United States International Trade Commission

Investigation No. 332-520

USITC Publication 4181

September 2010

Pharmaceutical 

Products and Chemical 

Intermediates, Fourth 

Review: Advice 

Concerning the 

Addition of Certain 

Products to the 

Pharmaceutical 

Appendix to the HTS
Address all communications to 

Secretary to the Commission 

United States International Trade Commission 

Washington, DC 20436

U.S. International Trade Commission

Robert B. Koopman

Acting Director of Operations

Karen Laney

Director, Office of Industries

COMMISSIONERS 

 

Deanna Tanner Okun, Chairman 

Charlotte R. Lane 

Daniel R. Pearson 

Shara L. Aranoff 

Irving A. Williamson 

Dean A. Pinkert
U.S. International Trade Commission

Washington, DC 20436 

www.usitc.gov

Publication 4181 September 2010

Pharmaceutical Products and Chemical 

Intermediates, Fourth Review: Advice 

Concerning the Addition of Certain 

Products to the Pharmaceutical Appendix 

to the HTS

Investigation No. 332-520
This report was prepared principally by the Office of Industries 

Project Leader and Principal Author 

Philip Stone 

philip.stone@usitc.gov 

With assistance from 

Elizabeth Nesbitt, Office of Industries 

Primary Reviewers 

Brian Allen, Office of Industries 

Walker Pollard, Office of Economics 

Special Assistance 

Judy Bryant, Office of Industries 

Brenda Carroll, Office of Industries 

Under the direction of 

Dennis Rapkins, Chief 

Chemicals and Textiles Division
i 

Abstract

Under the Pharmaceutical Zero-for-Zero Initiative, which entered into force in 1995, the 

United States and its major trading partners eliminated tariffs on many pharmaceuticals, 

their derivatives, and certain chemical intermediates used to make pharmaceuticals. The 

U.S. list of pharmaceutical products and chemical intermediates that are eligible for dutyfree treatment under the agreement is presented in the Pharmaceutical Appendix to the 

Harmonized Tariff Schedule of the United States. This appendix is periodically updated 

to provide duty relief for additional products of this kind, including newly developed 

pharmaceuticals. This report provides advice on the fourth update to the agreement, in 

which approximately 735 products are proposed to receive duty-free treatment. In 2009, 

U.S. imports of products currently included in the Pharmaceutical Agreement totaled 

over $85 billion; U.S. exports of such products exceeded $41 billion. Industry sources 

provided trade estimates for just 12 percent of the items proposed for addition to the 

agreement and estimated that the value of U.S. imports for these items alone would total 

$440 million in 2010. U.S. exports of the same items would likely reach or exceed $150 

million. Consequently, the U.S. import and export values in 2010 for all of the proposed 

items would likely be substantially larger than the estimates provided above. 

iii 

CONTENTS

Page

Abstract................................................................................................................................ i 

Executive Summary................................................................................................ v 

Chapter 1: Introduction ................................................................................... 1-1 Purpose and scope of study................................................................................................ 1-1 

 Description of products covered by the Initiative.............................................................. 1-2 

 

Chapter 2: Description of the Pharmaceutical 

 Appendix to the Harmonized Tariff Schedule 

 of the United States..................................................................................... 2-1 

 

Chapter 3: Estimates of Current U.S. Trade in the 

 Products Included in the Existing Pharmaceutical 

 Appendix and the Proposed Additions to the 

 Appendix................................................................................................................ 3-1 

Bibliography.................................................................................................................... Biblio-1 

Appendixes 

A. USTR Request Letter ............................................................................................................ A-1 

B. USITC’s Federal Register Notice of Institution................................................................... B-1 

C. Written submissions to the USITC ....................................................................................... C-1 

Boxes

1.1 Characteristics of the U.S. chemical and pharmaceutical industries..................................... 1-3 

Tables

1.1 U.S. chemical and pharmaceutical industries: Statistics for 2007 ........................................ 1-4 

3.1 Pharmaceutical products covered under chapter 30 and headings 2936, 2937, 2939, 

 and 2941 of the HTS: U.S. imports, exports, and trade balance, 2008–09 ..................... 3-2 
iv 

CONTENTS—Continued

Page

Tables—Continued

3.2 Products imported at the “K” special rate of duty for pharmaceuticals: U.S. imports for 

consumption, by six-digit HTS subheadings, 2008–09 .................................................. 3-4 

3.3 Proposed additions to the Pharmaceutical Appendix to the HTS for which submissions were 

received: Estimates for U.S. imports, exports, and trade balance, 2010......................... 3-7 
v 

Executive Summary

In 1995, the United States and 21 other countries agreed to eliminate tariffs on 

approximately 7,000 pharmaceutical products, their derivatives, and certain chemical 

intermediates used to manufacture pharmaceuticals. This agreement is known as the 

Pharmaceutical Zero-for-Zero Initiative. Since the original agreement entered into force, 

it has been updated three times—in 1997, 1999, and 2006—to expand the list of products 

that can be imported free of duty. This report provides advice to the United States Trade 

Representative (USTR) concerning the products proposed for the fourth update. 

The list of pharmaceutical products in the Pharmaceutical Appendix (Appendix) to the 

Harmonized Tariff Schedule of the United States (HTS) has grown substantially since 

1995. As a result of the first update, 496 items were added to the Appendix. The second 

update introduced an additional 642 items. The third update added 1,298 items. The 

current update includes 381 drugs identified by their international nonproprietary names 

(INNs), 17 prefixes and suffixes to identify derivatives of the INNs, and 354 chemical 

intermediates. When the current update is completed, the Appendix will include more 

than 10,000 products. The USTR compiled this list of new products using submissions 

from U.S. pharmaceutical firms and the other signatory countries. 

Pharmaceutical products covered in the Pharmaceutical Zero-for-Zero Initiative can be 

imported either as bulk active ingredients or in dosage forms that can be packaged for 

retail sale. Products in dosage form are generally classified under chapter 30 of the HTS, 

where most of the subheadings are duty-free. Many of the bulk pharmaceutical active 

ingredients and chemical intermediates are classified under HTS subheadings that also 

contain non-pharmaceutical products and have rates of duty ranging from 0 to 6.5 percent 

ad valorem. In order for pharmaceutical products classified under these HTS subheadings 

to be imported free of duty, they must be listed in the Appendix. 

The Appendix consists of three tables. The first table lists the INNs of pharmaceutical 

active ingredients that are eligible for duty-free treatment. The second table consists of 

chemical prefixes and suffixes that may be combined with the INNs to specify 

pharmaceutical derivatives that are also included in the agreement. The third table 

specifies the chemical intermediates for which duties have been eliminated. 

U.S. imports of products included in the Pharmaceutical Appendix totaled over $85 

billion in 2009; U.S. exports of these products exceeded $41 billion.1

 The pharmaceutical 

industry has estimated the effect on U.S. imports for only about 12 percent of the items 

proposed for inclusion in the Appendix. These items alone are expected to account for 

approximately $440 million of U.S. imports in 2010. U.S. International Trade 

Commission staff estimates that U.S. exports of the proposed items will reach or exceed 

$150 million in 2010 based on information submitted by the industry. A more precise 

estimate of imports and exports of items included in this update is not possible for many 

reasons, including the level of aggregation of many of the HTS provisions, uncertainty 

about final regulatory approval for many of the drugs, and the high proportion of 

proprietary data in this industry. 

 1

 The total value for U.S. imports is the sum of the trade under the specific HTS provisions and trade 

under the special tracking code for the Pharmaceutical Agreement. Since the tracking code does not apply to 

exports, the total value presented for U.S. exports under the agreement is a lower bound estimate. 

1-1 

CHAPTER 1 

Introduction 

Purpose and Scope of Study 

During the Uruguay Round trade negotiations, the United States and several of its major 

trading partners agreed to eliminate tariffs on pharmaceutical products, certain 

derivatives, and certain chemical intermediates used in the production of 

pharmaceuticals. 1 This agreement is known as the Pharmaceutical Zero-for-Zero 

Initiative (Initiative or Pharmaceutical Agreement). Effective January 1, 1995, the 

Pharmaceutical Agreement eliminated tariffs in signatory countries on approximately 

7,000 pharmaceutical products and chemical intermediates for all World Trade 

Organization members on a non-discriminatory basis. In the Uruguay Round Agreements 

Act (URAA), Congress authorized the President to grant duty-free treatment to new 

pharmaceutical products and chemical intermediates through periodic updates to the 

Pharmaceutical Agreement.2

 One of the requirements in the URAA is that the President 

obtain advice from the U.S. International Trade Commission (the Commission or USITC) 

about the proposed additions.3

 This report provides information about pharmaceutical 

products proposed for the fourth update to the Pharmaceutical Agreement.4

 As requested 

by the USTR, the report contains the following information: (1) a summary description 

of the products currently covered under the Initiative, as set out in the Pharmaceutical 

Appendix (Appendix) to the Harmonized Tariff Schedule of the United States (HTS), and 

those proposed to be added to that Appendix; (2) an explanation of the relationship 

between the various elements in the Appendix and the HTS; and (3) an estimate of 

current U.S. imports and, where possible, current U.S. exports of the products included in 

the current Appendix and the proposed additions to the Appendix, based on product 

groupings as necessary.5

 1

 Originally numbering 22, there are currently 34 signatories to the pharmaceutical agreement: 

Australia, Canada, the EU-27 (Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, 

Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, 

Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and the United Kingdom), 

Japan, Norway, Switzerland, the United States, and Macao. 2

 Section 111(b) of the Uruguay Round Agreements Act (URAA) (19 U.S.C. §3521(b)). 3

 Section 115 of the URAA (19 U.S.C. §3521). 

4

 On March 12, 2010, the United States Trade Representative (USTR) published a Federal Register

notice (75 Fed. Reg. 11986) requesting public submissions of products to be included in the current update. 

The list currently under review contains products drawn from these public submissions and from lists of 

products proposed by other signatory countries. The original agreement has been updated three times—in 

1997, 1999, and 2006. The Commission prepared reports for each of the previous three updates. 5

 A copy of the request letter from the USTR, dated May 27, 2010, is included in appendix A of this 

report. On August 6, 2010, USTR staff provided the USITC with non-substantive revisions to the list of 

pharmaceutical products included with the request letter. The revised list is included in appendix A. The 

Federal Register notice of the U.S. International Trade Commission’s initiation of this investigation, dated 

June 15, 2010, is included in appendix B. 
1-2 

Description of Products Covered by the Initiative 

Pharmaceuticals (produced by firms in NAICS 3254, “Pharmaceutical and Medicine 

Manufacturing”)6

 are used to prevent, diagnose, treat, or cure diseases in humans and 

animals. Products included in the Pharmaceutical Agreement include dosage-form 

pharmaceuticals, bulk active pharmaceutical ingredients, and certain chemical 

intermediates used in the production of pharmaceuticals. 

 Dosage-form pharmaceuticals are those that have been prepared in forms, such as 

tablets or vials, that may be packaged for retail sale. They are generally sold to 

the final customer either as generic or brand-name products, by prescription or 

over the counter. 

 Bulk active pharmaceutical ingredients are produced or purchased by 

pharmaceutical firms and further processed into dosage-form products. 

 The chemical intermediates included under the Initiative are generally organic 

chemicals used as inputs in the production of pharmaceutical active ingredients. 

Chemical intermediates are produced by either pharmaceutical firms or specialty 

chemicals firms (NAICS 325199, “All Other Basic Organic Chemical 

Manufacturing”) 7 and usually used by pharmaceutical firms to produce 

pharmaceutical products. The closer a chemical intermediate is to the final 

pharmaceutical, the more likely it is to be produced by a pharmaceutical firm.8

 

Although large firms account for most pharmaceutical production and exports, industry 

sources indicate that small and medium-sized enterprises that export benefit from the 

Pharmaceutical Agreement in several ways, including (1) duty elimination, (2) ease of 

program use, (3) the establishment of a “level playing field,” and (4) the establishment of 

a consistent trading environment. 9 A brief profile of certain characteristics of the 

chemical and pharmaceutical industries is provided in Box 1.1. 

 6

 The North American Industry Classification System (NAICS) is the industry classification system 

used by the U.S. Census Bureau and other statistical agencies. See U.S. Department of Commerce, Census 

Bureau, North American Industry Classification System (NAICS). 7

 NAICS 325199 comprises firms primarily engaged in manufacturing basic organic chemical products, 

excluding aromatic petrochemicals, industrial gases, synthetic organic dyes and pigments, gum and wood 

chemicals, cyclic crudes and intermediates, and ethyl alcohol. See U.S. Department of Commerce, Census 

Bureau, North American Industry Classification System (NAICS). 8

 Pharmaceutical companies may produce final and intermediate products by either fermentation, 

traditional chemical synthesis, or a combination of the two. Specialty chemical companies that supply 

intermediates to drug companies generally use traditional chemical synthesis. Future advances in 

biotechnology may allow more specialty chemicals and pharmaceuticals to be produced via fermentation or 

enzymatic processes. See USITC, Industrial Biotechnology, 2008. 9

 See USITC, Small and Medium-Sized Enterprises, 2010, 5-7. 
1-3 

 

Most products covered in the Pharmaceutical Agreement are classified in chapters 29 and 

30 of the HTS. Dosage-form pharmaceuticals are classified in chapter 30, 

“Pharmaceutical Products.” Most of the bulk pharmaceutical and chemical intermediates 

are organic chemicals classified in chapter 29 according to their chemical structure, 

occasionally under 8-digit HTS subheadings specifically applicable to drugs. Many of the 

bulk active pharmaceutical ingredients are classified under the following headings in 

chapter 29: 

HTS heading 2936 Provitamins and vitamins 

HTS heading 2937 Hormones 

HTS heading 2939 Alkaloids 

HTS heading 2941 Antibiotics 

Data for the chemical industry (NAICS 325), pharmaceutical industry (NAICS 3254), 

and “All Other Basic Organic Chemical Manufacturing” (NAICS 325199)10 in 2007, the 

latest year for which data are available from the Census Bureau, are shown in table 1.1. 

Shipments for the chemical and allied products industry totaled approximately $723 

billion; the pharmaceutical industry accounted for 26 percent of this amount. According 

more recently published data, the value of shipments for both industries rose steadily 

 10 While this category includes most firms that produce chemical intermediates for the pharmaceutical 

industry, it also includes many firms not connected with producing these products. 

Box 1.1 Characteristics of the U.S. chemical and pharmaceutical industries 

 The pharmaceutical and chemical industries include many large, multinational firms that often 

have manufacturing facilities throughout North America, Europe, and Asia. In the United 

States, pharmaceutical production facilities are concentrated in California, New Jersey, New 

York, and Pennsylvania, while chemical firms have manufacturing plants throughout the 

country. 

 Both industries spend large amounts of money on research and development (R&D), with the 

amounts increasing annually. The pharmaceutical industry spent an estimated $65.3 billion on 

R&D in 2009, up from $63.7 billion in 2008. In comparison, R&D spending by the U.S. 

chemical industry, excluding pharmaceuticals, was valued at $11.7 billion in 2008. 

 Much of the R&D spending by the pharmaceutical industry was used in the development of 

new drugs. Only 1 in every 5,000 pharmaceuticals tested is likely to receive approval from the 

U.S. Food and Drug Administration (FDA). The average cost of developing a successful new 

medicine is estimated to be about $1.3 billion over 10 to 15 years. Since firms in other 

chemical sectors typically do not face as stringent a regulatory system as pharmaceutical 

companies do, product development in these sectors is generally faster and less expensive. 

 Patent protection is also important to both industries. In the United States, firms receive 

exclusive rights to sell chemicals or pharmaceuticals for 20 years. However, for 

pharmaceuticals, the length of the product approval process can significantly reduce the 

patent holder’s period of exclusivity. U.S. patent law thus allows pharmaceutical patents to be 

extended to offset approval delays when certain conditions are met. After the patent expires, 

the product may quickly face competition from generic copies. 

Sources: Pharmaceutical Research and Manufacturers of America, Pharmaceutical Industry Profile 2010, 26, 

27; American Chemistry Council (ACC), Guide to the Business of Chemistry 2009, 73; 35 U.S.C. § 156. 
1-4 

during 2001–08.11 A decline in shipments in 2009 was primarily attributable to the global 

recession. In terms of trade, the pharmaceutical industry accounted for 45 percent of U.S. 

chemical imports and 25 percent of U.S. chemical exports in 2007. Employment in the 

pharmaceutical industry accounts for 31 percent of total employment in the chemical 

industry and 26 percent of its production workers. 

TABLE 1.1 U.S. chemical and pharmaceutical industries: Statistics for 2007 

Industry 

Total 

shipmentsa U.S. 

importsb U.S. exportsb Trade balance

U.S.

apparent 

consumption

Total 

employmenta Production 

workersa

Billion $ 1,000 persons 

NAICS 325: 

 Chemical 

 manufacturing 722.5 160.3 147.4 -12.9 735.5 801.6 463.8

NAICS 3254: 

 Pharmaceutical and 

 medicine 

 manufacturing 188.5 71.8 36.7 -35.2 223.7 250.4 122.0

NAICS 325199: 

 All other basic 

 organic chemical 

 manufacturing 80.5 20.3 29.7 9.4 71.0 68.4 40.8

Source: Official statistics of the U.S. Department of Commerce. 

a U.S. Department of Commerce, Census Bureau, 2007 Economic Census. b USITC, DataWeb. 

 11 Shipments by the chemical industry increased from $438.4 billion in 2001 to $750.5 billion in 2008 

before declining to $674.1 billion in 2009. Shipments by pharmaceuticals firms totaled $130.0 billion in 

2001, $194.4 billion in 2008, and $190.6 billion in 2009. See ACC, Guide to the Business of Chemistry 2010, 

14, 38. 
2-1 

CHAPTER 2 

Description of the Pharmaceutical Appendix 

to the Harmonized Tariff Schedule of the 

United States 

There are two ways that pharmaceutical products, their derivatives, and certain chemical 

intermediates covered under the Pharmaceutical Agreement enter the United States free 

of duty. The first way involves products listed under most headings in chapter 30 of the 

HTS (“Pharmaceutical Products”) and under the HTS chapter 29 headings 2936, 2937, 

2939, and 2941 (bulk vitamins, hormones, alkaloids, and antibiotics, respectively); for 

these products, the column 1 general rates of duty were reduced to zero when the 

Pharmaceutical Agreement went into effect on January 1, 1995. 1 The second way 

involves bulk active pharmaceutical ingredients and chemical intermediates used in their 

manufacture that are not classified in the four headings of chapter 29 listed above. These 

products receive duty-free treatment because they are listed in the Pharmaceutical 

Appendix to the HTS. 

As described in general note 13 of the HTS, a pharmaceutical product or chemical 

intermediate imported under an 8-digit HTS subheading that has the symbol “K” in the 

special-rate-of-duty column2

 is eligible for duty-free treatment only if it is listed in the 

Pharmaceutical Appendix. The Appendix is necessary for identifying such products 

because the 8-digit HTS subheadings that have the “K” symbol generally cover a large 

range of goods, many of which may not be pharmaceuticals or otherwise included in the 

Pharmaceutical Agreement. The special duty rates are available for imports from all 

countries eligible for column 1 general rates of duty.3

In other words, when a new pharmaceutical is available for use, it is immediately eligible 

for duty-free treatment if it is classified in chapter 30 of the HTS because it is in dosage 

form and/or packaged for sale, or if it is classified as a bulk pharmaceutical under one of 

the four specified HTS headings in chapter 29 (headings 2936, 2937, 2939, and 2941). 

However, if this new pharmaceutical is imported in bulk under another HTS heading and 

is not already included in the Pharmaceutical Appendix, it may be added to the duty-free 

list in the Appendix only during a periodic update; this is also the situation for chemical 

 1

 Chapter 30 of the HTS contains pharmaceutical products such as medicaments for human and 

veterinary use as well as other medical items, such as bandages and surgical equipment. Two subheadings in 

this chapter are not duty free: 3006.70.00 (“Gel preparations...”), which has a duty of 5 percent ad valorem, 

and 3006.91.00 (“Appliances identifiable for ostomy use”), which has a duty of 4.2 percent ad valorem. One 

item in heading 2941 is not free of duty: subheading 2941.20.10 (“Dihydrostreptomycin and its derivatives”) 

has an ad valorem tariff rate of 3.5 percent. 2

 Special rates of duty are the rates applied under one or more special tariff treatment programs, such as 

the Pharmaceutical Zero-for-Zero Initiative or various free trade agreements. See general note 3 of the HTS. 3

 There are three additional ways that a product covered by the Pharmaceutical Agreement can enter the 

United States free of duty: (1) a pharmaceutical or chemical intermediate that originates in a country that is a 

partner under a free trade or trade promotion agreement may be imported free of duty under that trade 

agreement rather than the Pharmaceutical Agreement; (2) some items in the Pharmaceutical Appendix may 

be classified under HTS tariff lines outside of chapter 30 and headings 2936, 2937, 2939, and 2941 that have 

a column 1 general rate of duty of “Free”; and (3) an item that is covered by one of the temporary duty 

provisions in chapter 99 of the HTS may be imported under that provision rather than the Pharmaceutical 

Agreement. 
2-2 

intermediates used to make new pharmaceuticals that are not yet covered by the 

Agreement. 

 The Pharmaceutical Appendix to the HTS comprises three tables. Table 1 lists 

pharmaceuticals by their international nonproprietary names (INNs). The Chemical 

Abstract Service (CAS) number for the product is also given for most items in this table.4

When the Pharmaceutical Agreement originally took effect, table 1 contained the 

pharmaceuticals listed in the World Health Organization (WHO) proposed INN lists 1–

69.5

 The first three updates of the Pharmaceutical Agreement added INNs from the WHO 

lists 70–93 to table 1 of the Pharmaceutical Appendix. The proposed update addressed in 

this report includes 381 products from WHO proposed INN lists 94–99. 

Table 2 of the Pharmaceutical Appendix contains prefixes and suffixes that can be 

combined with the INNs of table 1 to specify derivative products, such as salts, esters, 

and hydrates, which are also eligible for duty-free treatment. As stated in general note 13 

of the HTS, the derivative product formed from a combination of items in tables 1 and 2 

must be classifiable in the same 6-digit tariff provision as the original product listed in 

table 1 in order for it to receive duty-free treatment. Since items in table 1 can be 

combined with multiple items in table 2 to form derivative products, it is difficult to 

enumerate the total number of products that may be eligible for duty-free treatment under 

the Pharmaceutical Agreement. Under the original Agreement, 310 prefixes and suffixes 

were listed in table 2. The first three updates added a total of 103 items to this table. The 

current update would add 17 prefixes and suffixes to table 2. 

 Table 3 lists chemical intermediates used in the production of pharmaceutical products. 

Most of these chemicals are classified in either chapter 29 or chapter 39 of the HTS; a 

few are found in chapters 28, 32, 34, and 38.6

 The Pharmaceutical Agreement originally 

included over 300 chemical intermediates in table 3. The previous updates added 1,072 

intermediates. In the current update, the parties to the Pharmaceutical Agreement propose 

to add 354 chemical intermediates to table 3. 

 4

 The Chemical Abstract Service (CAS), a division of the American Chemical Society, manages CAS 

numbers, which are unique identifiers of chemical substances. Inclusion of CAS numbers for items in the 

Pharmaceutical Appendix eases the burden of customs officials examining import documentation by 

providing an unambiguous way of identifying a chemical product that may have many systematic, generic, 

proprietary, or common names. Since a CAS number is unique to the chemical it identifies, the CAS number 

can be linked to the HTS classification of the chemical. U.S. Customs and Border Protection’s CROSS 

database (http://rulings.cbp.gov/ (accessed August 26, 2010)) links CAS numbers with the appropriate HTS 

classifications but only covers a small portion of all CAS numbers. The European Commission’s ECICS 

database (http://ec.europa.eu/taxation_customs/dds/cgi-bin/ecics2home?Periodic=0&Lang=EN (accessed 

August 26, 2010)) maps the CAS number of a chemical to that chemical’s appropriate classification in the 

European Commission’s Combined Nomenclature and may cover more CAS numbers than the CROSS 

database. In some cases, the ECICS database provides information about the molecular structure of the 

chemical that is helpful to determine how the chemical is classified in the HTS. However, by law, only the 

U.S. Customs Service is authorized to issue a binding ruling on the classification of a specific chemical. 5

 WHO proposed INN lists can be found at 

http://www.who.int/medicines/publications/druginformation/innlists/en/index.html (accessed July 8, 2010). 6

 Chapter 29, where most bulk pharmaceutical products and chemical intermediates are classified, has a 

total of 973 tariff lines. Of these tariff lines, 271 have a column 1 general rate of duty of “Free” and 325 have 

the symbol “K” in the special-rate-of-duty column. Most of the products in the current update are likely to be 

classified in tariff lines that currently have the symbol “K” in the special-rate-of-duty column. However, 

there are legal procedures by which a new “K” symbol could be added to an existing tariff line if necessary. 
3-1 

CHAPTER 3 

Estimates of Current U.S. Trade in the 

Products Included in the Existing 

Pharmaceutical Appendix and the Proposed 

Additions to the Appendix

Total trade in products from HTS chapter 30 and HTS headings 2936, 2937, 2939, and 

2941 was valued at more than $102.0 billion in 2009, an increase from more than $97 

billion in 2008. Much of the increase was the result of growth in U.S. exports in 2009. As 

the domestic market for chemicals started slowing in early 2008, many companies 

focused on foreign markets.1

 But by late 2008, these markets started slowing, too. In 

2009, imports of many of these products increased, particularly those classified under 

chapter 30 and those tracked by the “K” special-rate-of-duty code, due in most part to 

increases in imports from Germany, Singapore, and the United Kingdom; related-party 

trade also played a role as many of the companies are multinational. Looking at the trade 

data in more detail for 2008 and 2009, the share of total trade accounted for by chapter 30 

increased from 89 percent to 93 percent and the shares of each of the four specified HTS 

headings of chapter 29 declined. U.S. imports and exports of products classified in 

chapter 30 increased over the two years. Much of the trade in pharmaceuticals, including 

imports into the U.S. market, is in products that are shipped to the intended market for 

final formulation and/or packaging to meet domestic regulations. Table 3.1 provides 

values of U.S. imports for consumption, domestic exports, and the trade balance for HTS 

chapter 30 and HTS headings 2936, 2937, 2939, and 2941.2

U.S. imports of products currently listed in the Pharmaceutical Appendix and tracked 

using the “K” special-rate-of-duty code were valued at approximately $23.4 billion in 

2008 and $25.2 billion in 2009;3

 the ad valorem equivalent tariff rate for these products 

would have been 6.2 percent in 2009 if they had not received duty-free treatment.4

 Tables 

3.1 and 3.2 present trade data for the products imported under the Pharmaceutical Zerofor-Zero Initiative in 2008 and 2009. The total value of U.S. imports under the 

Pharmaceutical Agreement in 2009 ($85.2 billion) can be obtained by adding the value of 

 1

 USITC, Shifts in U.S. Merchandise Trade 2008, 2009, CH-1–CH-4. 

2

 As noted in chapter 2 of this report, the subheadings in HTS chapter 30 and headings 2936, 2937, 

2939, and 2941 are duty-free except for subheadings 3006.70.00, 3006.91.00, and 2941.20.10. Imports and 

exports for items in these three subheadings are included in the values in table 3.1. In 2009, the value of U.S. 

imports for consumption came to $2.5 million for 3006.70.00, $64.8 million for 3006.91.00, and $0.4 million 

for 2941.20.10. Domestic exports came to $21.9 million for 3006.70.00, $137.0 million for 3006.91.00, and 

$0.3 million for 2941.20.10 in 2009. 3

 Equivalent export data are not available because export data are generally aggregated at a higher level 

than import data and because the preference program and tariff rates only apply to imports. 4

 The ad valorem equivalent tariff rate for products in the Pharmaceutical Appendix was calculated by 

dividing the sum of duties that would have been collected in 2009 if the products had not received duty-free 

treatment by the total value of imports for the products in that year. 
3-2 

“K” code imports in 2009 ($25.2 billion) and the value of imports classified under 

chapter 30 and the four specified HTS headings ($60.2 billion).5

TABLE 3.1 Pharmaceutical products covered under chapter 30 and headings 2936, 2937, 2939, and 2941 

of the HTS: U.S. imports, exports, and trade balance, 2008–09 (million $) 

Product grouping 2008 2009

U.S. imports for consumption: 

 2936 1,185 1,021

 2937 1,861 1,271

 2939 2,634 937

 2941 1,265 912

 Chapter 30 52,801 56,027

 Total 59,747 60,167

U.S. domestic exports: 

 2936 601 507

 2937 2,010 2,184

 2939 47 39

 2941 1,220 718

 Chapter 30 33,381 38,416

 Total 37,259 41,864

U.S. trade balance: 

 2936 -584 -513

 2937 149 913

 2939 -2,587 -898

 2941 -45 -194

 Chapter 30 -19,420 -17,611

 Total -22,487 -18,303

Source: Official statistics of the U.S. Department of Commerce. 

Because HTS subheadings that have the “K” special-rate-of-duty code cover multiple 

products, many of which are not included in the Pharmaceutical Agreement, the USITC 

cannot project the value of eventual trade that may result from the proposed additions to 

the Pharmaceutical Appendix based on current trade data. The Commission’s Federal 

Register notice for this study requested written submissions containing estimates for 

future trade in the proposed items. 6 The USITC received five submissions. 7 The 

projections found in these submissions, which included data for about 12 percent of the 

items in the current update, valued U.S. imports at $440.0 million for 2010 (table 3.3).8

 

USITC staff estimates that U.S. exports will reach or exceed $150.0 million for the items 

covered in these submissions. 

Because these trade estimates cover such a small portion of the items proposed for 

inclusion in the Pharmaceutical Appendix, these data may not adequately reflect the 

 5

 While the duty-free treatment under the Pharmaceutical Agreement applies to all countries eligible for 

the column 1 rate of duty, most U.S. trade in pharmaceuticals and chemical intermediates is with the other 33 

signatory countries. The other signatory countries accounted for 83.5 percent of U.S. imports under chapter 

30 and subheading 2836, 2937, 2939, and 2941 in 2008 and 82.9 percent in 2009. For U.S. exports of these 

products, 86.0 percent went to other signatory countries in 2008 and 85.2 percent in 2009. For U.S. imports 

under the “K” special rate of duty, 91.1 percent originated in signatory countries in 2008 and 84.6 percent in 

2009. 6

 See appendix B. 

7

 The public versions of the four submissions from PhRMA and one submission from Rochem 

International Inc. are included in appendix C. 8

 Submissions included data for 89 of the 735 pharmaceuticals and chemical intermediates in the 

current update. The data on U.S. imports in table 3.3 have been aggregated to prevent disclosure of business 

proprietary information. 
3-3 

possible size of the trade that might occur when the duties are eliminated. The data are 

limited for many reasons, including the following: 

 

(1) Data on many individual products are proprietary and not publicly available; 

(2) Data for bulk pharmaceutical active ingredients are often aggregated with data 

for chemicals that are not included in the Pharmaceutical Agreement; 

(3) The proposed items may not be traded in the near future or, in fact, at any time 

(e.g., some may still be awaiting regulatory approval); and 

(4) As mentioned in Chapter 2, estimates cannot be provided for the multitude of 

possible drug derivatives that may be imported free of duty by combining the 

prefixes or suffixes from table 2 of the Pharmaceutical Appendix with the 

INNs listed in table 1.
3-4 

TABLE 3.2 Products imported at the “K” special rate of duty for pharmaceuticals: U.S. imports for 

consumption, by six-digit HTS subheadings, 2008–09 (actual $) 

U.S. imports 

Six-digit HTS subheading 2008 2009

283329 36,866 2,388

284190 28,208 0

284210 135,188 120,562

284290 4,973 36,207

284330 19,563 0

284390 16,640,223 10,284,440

284690 890,973 27,323

290322 373,979 47,614

290339 466,990 588,376

290345 0 0

290346 0 4,590

290347 0 0

290349 1,519,855 3,028,310

290351 0 0

290359 1,102,996 158,878

290362 0 0

290369 128,632 499,844

290410 6,682 0

290490 9,750 88,875

290519 102,415 25,701

290522 57,488 112,289

290529 221,945 0

290539 89,500 89,500

290549 80,052 0

290559 3,275,420 13,884,085

290611 1,772,825 2,414,627

290619 1,834,804 1,842,747

290629 48,279 2,717

290719 305,519 270,807

290729 819,957 525,475

290819 5,111,340 2,169,206

290899 0 288,750

290919 65,660,338 66,337,127

290920 141,960 2,750

290930 54,606 113,407

290949 1,110,289 775,591

290950 28,257,371 28,163,670

291030 42,372 23,000

291090 991,215 0

291100 535,925 1,343,563

291219 7,832,799 11,084,855

291229 247,793 396,355

291249 26,828 12,524

291419 240,449 197,046

291429 748,044 531,093

291439 629,780 117,440

291440 84,941 116,364

291450 39,470,186 37,978,706

291469 53,399,394 40,987,697

291470 1,852,784 2,091,205

291529 258,171 88,903

291539 5,220,675 4,645,396

291540 0 0

291550 0 32,869

291590 34,427,097 29,687,905

291619 413,168 9,551

291620 12,769,068 11,466,001

291631 496,861 560,886

291639 8,960,790 2,027,476
3-5 

TABLE 3.2 Products imported at the “K” special rate of duty for pharmaceuticals: U.S. imports for 

consumption, by six-digit HTS subheadings, 2008–09 (actual $)—Continued

U.S. imports 

Six-digit HTS subheading 2008 2009 

291713 5,900 130,757

291719 834,259 148,543

291720 59,108 78,645

291734 230,429 116,184

291739 0 0

291811 34,184 0

291813 51,200 15,848

291816 373,643 295,113

291818 34,431 0

291819 19,968,036 15,325,357

291822 0 0

291823 3,373,893 3,770,195

291829 1,802,019 1,557,797

291830 1,165,355 1,602,548

291899 66,743,722 41,879,898

291910 7,612 0

291990 995,125 520,101

292019 0 180,000

292090 2,425,093 3,655,663

292119 30,864,708 22,230,405

292129 258,647 196,351

292130 1,554,303 4,089,673

292142 598,350 306,956

292143 0 0

292145 0 0

292149 56,387,085 49,713,738

292159 1,455,811 242,695

292211 46,400 26,271

292212 0 0

292219 484,851,037 524,682,337

292229 16,851,716 1,866,046

292239 45,917,788 46,378,435

292241 3,677,154 1,095,896

292242 1,254,874 1,659,219

292243 0 0

292249 795,288,687 831,121,356

292250 432,422,790 394,905,811

292310 1,726,469 2,180,940

292320 3,691,567 667,247

292390 36,658,315 27,604,867

292419 30,600,885 23,642,182

292421 97,235 102,624

292423 4,776 0

292429 236,177,339 277,698,615

292519 434,777 64,005

292529 62,778,275 53,295,344

292690 31,124,331 24,950,913

292700 9,336,363 10,167,851

292800 17,869,129 13,189,570

292990 59,636 53,011

293020 1,933,692 540,096

293030 652,113 596,615

293090 91,862,733 51,648,732

293100 56,978,881 37,567,701

293219 17,738,294 17,832,569

293221 1,140,350 1,403,016

293229 305,209,610 263,259,341
3-6 

TABLE 3.2 Products imported at the “K” special rate of duty for pharmaceuticals: U.S. imports for 

consumption, by six-digit HTS subheadings, 2008–09 (actual $)—Continued

U.S. imports 

Six-digit HTS subheading 2008 2009 

293299 251,856,862 246,080,131

293311 35,937 0

293319 144,728 276,170

293321 1,381,895 282,764

293329 255,804,439 46,216,945

293339 1,126,930,720 1,329,460,225

293349 183,315,856 257,218,860

293354 0 12,188

293359 1,036,619,141 1,823,801,500

293369 77,322,319 57,922,230

293379 793,271,828 1,081,461,827

293399 5,052,280,495 6,623,112,632

293410 71,249,516 97,971,013

293420 323,469,449 497,169,066

293430 10,436,097 10,974,260

293499 10,053,206,458 7,453,935,740

293500 794,269,028 2,453,358,006

293810 838,483 1,178,036

293890 7,982,054 7,029,317

294000 30,272,406 23,211,335

294200 8,371,063 7,511,916

300670 28,633 0

320300 940,266 663,778

320413 13,200 35,157

320419 2,344,595 3,859,388

320490 63,565 52,715

340130 70,352 29,209

340213 5,826,792 753,856

340220 45,996 33,663

380850 221,295 163,503

380894 26,250 71,547

382490 41,833,169 43,729,336

390190 1,619 5,496

390290 187,810 125,634

390461 215,249 3,536

390591 265,593 0

390599 9,848,090 9,762,428

390690 2,275,446 1,556,498

390710 23,841 39,934

390720 895,163 2,944,237

390730 785,599 305,817

390760 664,671 268,785

390770 24,875 72,102

390799 103,424 30,484

390810 432,335 98,201

390910 3,554 485,387

390940 148,860 1,054,292

391000 687,357 498,464

391190 1,222,250 2,042,399

391220 28,031 38,640

391231 13,557,755 13,596,805

391239 5,263,255 3,254,414

391290 208,002 79,771
3-7 

TABLE 3.2 Products imported at the “K” special rate of duty for pharmaceuticals: U.S. imports for 

consumption, by six-digit HTS subheadings, 2008–09 (actual $)—Continued

U.S. imports 

Six-digit HTS subheading 2008 2009 

391390 13,606,816 12,745,760

391400 35,461,724 39,971,745

 Total 23,390,949,661 25,186,118,910

Source: Official statistics of the U.S. Department of Commerce. 

Note: Pharmaceutical products and chemical intermediates originating in a country that is a partner under a 

free trade or trade promotion agreement may be imported free of duty under that trade agreement rather than 

the Pharmaceutical Agreement. Import data for pharmaceutical products imported under various free trade 

agreements are not included in this table. 

TABLE 3.3 Proposed additions to the Pharmaceutical Appendix to the HTS for which submissions were 

received: Estimates for U.S. imports, exports, and trade balance, 2010 (actual $)

Product grouping U.S. importsa U.S. exportsb U.S. trade 

balance

Proposed additions to the Pharmaceutical Appendix 440,000,000 150,000,000 -290,000,000

Source: Compiled by USITC staff from the submissions of the PhRMA. 

 a Estimates include data submitted on 89 of approximately 735 pharmaceutical products and chemical 

intermediates under consideration. An aggregate estimate for U.S. imports has been reported to protect 

business confidential information. 

 b

 USITC staff estimate that the value of U.S. exports will reach or exceed this amount. Estimates are 

based on information submitted by the industry. 

Biblio-1 

Bibliography 

American Chemistry Council (ACC). Guide to the Business of Chemistry, 2009. Arlington, VA: ACC, 

2009. 

_____. Guide to the Business of Chemistry, 2010. Arlington, VA: ACC, 2010. 

Pharmaceutical Research and Manufacturers Association (PhRMA). Pharmaceutical Industry Profile 

2010. Washington, DC: PhRMA, March 2010. 

http://www.phrma.org/sites/phrma.org/files/attachments/Profile_2010_FINAL.pdf (accessed 

July 9, 2010). 

U.S. Department of Commerce. Census Bureau. 2007 Economic Census. 

http://www.census.gov/econ/census07/ (accessed July 13, 2010). 

U.S. Department of Commerce. Census Bureau. North American Industry Classification System (NAICS).

http://www.census.gov/eos/www/naics/ (accessed July 9, 2010). 

U.S. International Trade Commission. Industrial Biotechnology: Development and Adoption by the U.S. 

Chemical and Biofuel Industries. USITC Publication 4020. Washington, DC: USITC, 2008. 

_____. Interactive Tariff and Trade DataWeb. http://dataweb.usitc.gov/ (accessed July 12, 2010). 

_____. Shifts in U.S. Merchandise Trade 2008. USITC Publication 4089. Washington, DC: USITC, 2009. 

_____. Small and Medium-Sized Enterprises: U.S. and EU Export Activities, and Barriers and 

Opportunities Experienced by U.S. Firms. USITC Publication 4169. Washington, DC: USITC, 

2010. 

APPENDIX A 

USTR Request Letter

EXECUTIVE OFFICE OF THE PRESIDENT 

THE UNITED STATES TRADE REPRESENTATIVE 

WASHINGTON, D.C. 20508 

The Honorable Shara Aranoff 

Chairman 

United States International Trade Commission 

500 E Street, S.W. 

Washington, DC 20436 

Dear Chairman Aranoff: 

............................................ ( ~,~ 

OffIce of the 

Secretary 

Int'! Trade ComnllsslOn 

Opening markets through elimination of tariff barriers has been an ongoing objective of this 

Administration. As one part of the market access tariff results of the Uruguay Round 

negotiations, the United States and 21 other Members of the World Trade Organization (WTO) 

agreed to the reciprocal elimination of duties on approximately 7,000 pharmaceutical products 

and chemical intermediates used primarily for the production of pharmaceuticals 

(pharmaceuticals zero-for-zero initiative). 

Congress implemented the results of the Uruguay Round negotiations through the Uruguay 

Round Agreements Act (URAA). In section 111 (b) ofthe URAA, Congress authorized the 

President to proclaim further modification of any duty for articles contained in a tariff category 

that was part of a zero-for-zero initiative. The Statement of Administrative Action, which 

Congress approved in the URAA, notes that the President would use section 111 (b) authority to 

grant duty-free treatment for new pharmaceutical products. 

Participants in the pharmaceuticals zero-for-zero initiative have conducted periodic reviews to 

identify further products that could be covered by this duty elimination initiative. As a result of 

multilateral negotiations under the auspices of the WTO in 1996, 1998, and 2006, the United 

States and other participants in the initiative eliminated duties on an additional 496 

pharmaceutical items in the first update, 642 pharmaceutical items in the second update, and 823 

pharmaceutical items in the third update. The U.S. International Trade Commission has 

provided critical assistance to the Office of the U.S. Trade Representative USTR in these 

negotiations and in implementation of their results 

Participants in the pharmaceuticals zero-for-zero initiative are conducting a fourth review to 

determine if products can be added to the initiative. Pursuant to authority delegated to me by the 

President, I am requesting in accord with section 115 of the URAA and section 332 ofthe Tariff 

Act of 1930 that the Commission provide advice to USTR in the form of information on the 

pharmaceutical products and chemical intermediates proposed for addition to the 

pharmaceuticals zero-for-zero initiative. Specifically, I request that the Commission provide: 

(1) a summary description of the products currently covered under the initiative as set out in the 

Pharmaceutical Appendix to the U.S. Harmonized Tariff Schedule (Appendix) and those 

proposed to be added to that Appendix; (2) an explanation of the relationship between the 

various elements in the Appendix and the Harmonized Tariff Schedule of the United States; and 

A-3
The Honorable Shara Aranoff 

Page Two 

(3) an estimate of current u.s. imports and, where possible, current U.s. exports of the products 

included in the current Appendix and the proposed additions to the Appendix, based on product 

groupings as necessary. 

If data are not available for certain products, particularly in the case of new products, the advice 

may be provided in a qualitative form. I request that the Commission provide its advice at the 

earliest possible date, but not later than September 1,2010. The Commission's report will be 

made available to the general public in its entirety. Therefore, the report should not contain any 

confidential business or national security classified information. 

I appreciate your assistance and cooperation on this matter and look forward to working with you 

and your staff on these issues in the future. 

Ron Kirk 

Enclosures: 

- Table 1: Pharmaceutical INNs proposed for addition to the Pharmaceutical Appendix 

- Table 2: Pharmaceutical prefixes and suffixes proposed for addition to the Pharmaceutical Appendix 

- Table 3: Pharmaceutical intermediates proposed for addition to the Pharmaceutical Appendix 

A-4
Table 1 

International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical 

Appendix to the Harmonized Tariff Schedule 

INN CAS Number

Abagovomab 792921-10-9 

Aclidinium Bromide 320345-99-1 

Aderbasib 791828-58-5 

Adipiplon 840486-93-3 

Adoprazine 222551-17-9 

Afimoxifene 68392-35-8 

Aflibercept 862111-32-8 

Agatolimod 207623-20-9 

Alacizumab Pegol 934216-54-3 

Albiglutide 782500-75-8 

Albinterferon Alfa-2b 472960-22-8 

Alcaftadine 147084-10-4 

Aleglitazar 475479-34-6 

Aleplasinin 481629-87-2 

Alferminogene Tadenovec 473553-86-5 

Alipogene Tiparvovec 929881-05-0 

Almorexant 871224-64-5 

Alogliptin 850649-61-5 

Alvespimycin 467214-20-6 

Amibegron 121524-08-1 

Amifampridine 54-96-6 

Amolimogene Bepiplasmid 870524-46-2 

Amsilarotene 125973-56-0 

Anacetrapib 875446-37-0 

Anamorelin 249921-19-5 

Anrukinzumab 910649-32-0 

Apadenoson 250386-15-3 

Apilimod 541550-19-0 

Aplaviroc 461443-59-4 

Apremilast 608141-41-9 

Apricitabine 160707-69-7 

Apricoxib 197904-84-0 

Arbaclofen Placarbil 847353-30-4 

Arterolane 664338-39-0 

Atacicept 845264-92-8 

Axitinib 319460-85-0 

Azilsartan 147403-03-0 

Azilsartan Medoxomil 863031-21-4 

Azoximer Bromide 892497-01-7 

A-5
Bafetinib 859212-16-1 

Balamapimod 863029-99-6 

Baminercept 909110-25-4 

Bavituximab 648904-28-3 

Bederocin 757942-43-1 

Bedoradrine 194785-19-8 

Befiradol 208110-64-9 

Begacestat 769169-27-9 

Belinostat 414864-00-9 

Bentamapimod 848344-36-5 

Beperminogene Perplasmid 627861-07-8 

Beroctocog Alfa 9001-27-8 

Berubicin 677017-23-1 

Besifloxacin 141388-76-3 

Betrixaban 330942-05-7 

Bevasiranib 959961-96-7 

Bevirimat 174022-42-5 

Boceprevir 394730-60-0 

Bosutinib 380843-75-4 

Brecanavir 313682-08-5 

Bremelanotide 189691-06-3 

Briobacept 869881-54-9 

Brivanib Alaninate 649735-63-7 

Bucelipase Alfa 9026-00-0 

Cabazitaxel 183133-96-2 

Camobucol 216167-92-9 

Canakinumab (light chain) 402710-27-4 

Canakinumab (heavy chain) 402710-25-2 

Capadenoson 544417-40-5 

Capeserod 769901-96-4 

Carfilzomib 868540-17-4 

Cariprazine 839712-12-8 

Carisbamate 194085-75-1 

Carmegliptin 813452-18-5 

Casopitant 414910-27-3 

Catramilast 183659-72-5 

Catridecacog 606138-08-3 

Cediranib 288383-20-0 

Ceftaroline Fosamil 229016-73-3 

Celivarone 401925-43-7 

Cenersen 872847-66-0 

Cevipabulin 849550-05-6 

A-6
Cevoglitazar 839673-52-8 

Choline Fenofibrate 856676-23-8 

Cinaciguat 329773-35-5 

Citatuzumab Bogatox 945228-49-9 

Cobiprostone 333963-42-1 

Conatumumab 896731-82-1 

Conestat Alfa 80295-38-1 

Contusugene Ladenovec 600735-73-7 

Custirsen 903916-27-8 

Dacetuzumab 880486-59-9 

Dalcetrapib 211513-37-0 

Danusertib 827318-97-8 

Dapagliflozin 461432-26-8 

Daporinad 201034-75-5 

Darapladib 356057-34-6 

Darinaparsin 69819-86-9 

Darotropium Bromide 850607-58-8 

Dasatinib 302962-49-8 

Delimotecan 187852-63-7 

Demiditraz 944263-65-4 

Denagliptin 483369-58-0 

Denenicokin 716840-32-3 

Denibulin 284019-34-7 

Denosumab 615258-40-7 

Derquantel 187865-22-1 

Dexamethasone Cipecilate 132245-57-9 

Dexelvucitabine 134379-77-4 

Dexnebivolol 118457-15-1 

Diaplasinin 481631-45-2 

Dilopetine 247046-52-2 

Disitertide 272105-42-7 

Disomotide 181477-43-0 

Dovitinib 405169-16-6 

Drinabant 358970-97-5 

Dulanermin 867153-61-5 

Dutacatib 501000-36-8 

Edoxaban 480449-70-5 

Efungumab 762260-74-2 

Elacytarabine 188181-42-2 

Elagolix 834153-87-6 

Eldecalcitol 104121-92-8 

Elesclomol 488832-69-5 

A-7
Elocalcitol 199798-84-0 

Elsibucol 216167-95-2 

Eltrombopag 496775-61-2 

Elvitegravir 697761-98-1 

Emricasan 254750-02-2 

Entinostat 209783-80-2 

Epetirimod 227318-71-0 

Epoetin Kappa 879555-13-2 

Epoetin Theta 762263-14-9 

Eprodisate 21668-77-9 

Eprotirome 355129-15-6 

Eribaxaban 536748-46-6 

Eribulin 253128-41-5 

Esreboxetine 98819-76-2 

Etaracizumab 892553-42-3 

Ezatiostat 168682-53-9 

Fasobegron 643094-49-9 

Favipiravir 259793-96-9 

Faxeladol 433265-65-7 

Fermagate 119175-48-3 

Ferric Carboxymaltose 9007-72-1 

Ferroquine 185055-67-8 

Fimasartan 247257-48-3 

Firategrast 402567-16-2 

Flopristin 318498-76-9 

Flovagatran 871576-03-3 

Fluticasone Furoate 397864-44-7 

Folitixorin 3432-99-3 

Foravirumab 944548-38-3 

Fosalvudine Tidoxil 763903-67-9 

Fosaprepitant 172673-20-0 

Fospropofol 258516-89-1 

Gabapentin Enacarbil 478296-72-9 

Gamithromycin 145435-72-9 

Gantenerumab 89957-37-9 

Giripladib 865200-20-0 

Golotimod 229305-39-9 

Goxalapladib 412950-27-7 

Ibalizumab 680188-33-4 

Ibipinabant 464213-10-3 

Ibodutant 522664-63-7 

Idrabiotaparinux Sodium 405159-59-3 

A-8
Ilepatril 473289-62-2 

Imeglimin 775351-65-0 

Imepitoin 188116-07-6 

Imisopasem Manganese 218791-21-0 

Inakalant 335619-18-6 

Incyclinide 15866-90-7 

Indantadol 202844-10-8 

Inolitazone 223132-37-4 

Intiquinatine 445041-75-8 

Iodofiltic Acid (123I) 123748-56-1 

Ipilimumab 477202-00-9 

Iratumumab 640735-09-7 

Isavuconazole 241479-67-4 

Isavuconazonium Chloride 338990-84-4 

Lancovutide 1391-36-2 

Lapaquistat 189059-71-0 

Larazotide 258818-34-7 

Laromustine 173424-77-6 

Laropiprant 571170-77-9 

Larotaxel 156294-36-9 

Lensiprazine 327026-93-7 

Levamlodipine 103129-82-4 

Levomefolic Acid 31690-09-2 

Levomilnacipran 96847-55-1 

Levonadifloxacin 154357-42-3 

Levonebivolol 118457-16-2 

Lexatumumab 845816-02-6 

Lificiguat 170632-47-0 

Linaclotide 851199-59-2 

Linagliptin 668270-12-0 

Linopristin 325965-23-9 

Lisdexamfetamine 608137-32-2 

Litenimod 852313-25-8 

Lixisenatide 320367-13-3 

Lobeglitazone 607723-33-1 

Lodenafil Carbonate 398507-55-6 

Lonaprisan 211254-73-8 

Lorcaserin 616202-92-7 

Lucatumumab 903512-50-5 

Macitentan 441798-33-0 

Managlinat Dialanetil 280782-97-0 

Masilukast 136564-68-6 

A-9
Masitinib 790299-79-5 

Mavacoxib 170569-88-7 

Melogliptin 868771-57-7 

Metenkefalin 58569-55-4 

Methylnaltrexone Bromide 73232-52-7 

Mifamurtide 83461-56-7 

Migalastat 108147-54-2 

Milatuzumab 899796-83-9 

Milveterol 652990-07-3 

Mimopezil 180694-97-7 

Mipomersen 1000120-98-8 

Mirabegron 223673-61-8 

Mirodenafil 862189-95-5 

Monepantel 887148-69-8 

Motavizumab 677010-34-3 

Motesanib 453562-69-1 

Naproxcinod 163133-43-5 

Naptumomab Estafenatox 676258-98-3 

Nelivaptan 439687-69-1 

Nemonoxacin 378746-64-6 

Nepidermin 62253-63-8 

Neratinib 698387-09-6 

Nesbuvir 691852-58-1 

Nilotinib 641571-10-0 

Nimotuzumab 828933-51-3 

Niraxostat 206884-98-2 

Obatoclax 803712-67-6 

Obinepitide 348119-84-6 

Obinutuzumab 949142-50-1 

Ocrelizumab 637334-45-3 

Odanacatib 603139-19-1 

Oglemilast 778576-62-8 

Olaparib 763113-22-0 

Olesoxime 22033-87-0 

Omacetaxine Mepesuccinate 26833-87-4 

Ombrabulin 181816-48-8 

Omtriptolide 195883-06-8 

Orvepitant 579475-18-6 

Otelixizumab 881191-44-2 

Otenabant 686344-29-6 

Ovemotide 181477-91-8 

Ozarelix 295350-45-7 

A-10
Ozenoxacin 245765-41-7 

Padeliporfin 759457-82-4 

Pafuramidine 186953-56-0 

Palifosfamide 31645-39-3 

Palovarotene 410528-02-8 

Pamapimod 449811-01-2 

Panobinostat 404950-80-7 

Paquinimod 248282-01-1 

Pardoprunox 269718-84-5 

Parogrelil 139145-27-0 

Pazopanib 444731-52-6 

Pegloticase 885051-90-1 

Perampanel 380917-97-5 

Peretinoin 81485-25-8 

Pexacerfont 459856-18-9 

Pimavanserin 706779-91-1 

Piragliatin 625114-41-2 

Pitolisant 362665-56-3 

Pomalidomide 19171-19-8 

Posaraprost 172740-14-6 

Pramiconazole 219923-85-0 

Preladenant 377727-87-2 

Prinaberel 524684-52-4 

Pyronaridine 74847-35-1 

Quarfloxin 865311-47-3 

Rabeximod 872178-65-9 

Radezolid 869884-78-6 

Radiprodil 496054-87-6 

Rafivirumab 944548-37-2 

Raltegravir 518048-05-0 

Regrelor 787548-03-2 

Relacatib 362505-84-8 

Remogliflozin Etabonate 442201-24-3 

Resatorvid 243984-11-4 

Retaspimycin 857402-23-4 

Retosiban 820957-38-8 

Ridaforolimus 572924-54-0 

Rilapladib 412950-08-4 

Rilonacept 501081-76-1 

Riociguat 625115-55-1 

Rolapitant 552292-08-7 

Rolipoltide 698389-00-3 

A-11
Rolofylline 136199-02-5 

Romidepsin 128517-07-7 

Romiplostim 267639-76-9 

Ronacaleret 753449-67-1 

Ropidoxuridine 093265-81-7 

Rosabulin 501948-05-6 

Rosonabant 861151-12-4 

Rotigaptide 355151-12-1 

Rusalatide 497221-38-2 

Sagopilone 305841-29-6 

Salirasib 162520-00-5 

Sapacitabine 151823-14-2 

Saracatinib 379231-04-6 

Semagacestat 425386-60-3 

Semuloparin Sodium 9041-08-1 

Senicapoc 289656-45-7 

Sergliflozin Etabonate 408504-26-7 

Simotaxel 791635-59-1 

Sitagliptin 486460-32-6 

Sitimagene Ceradenovec 898830-54-1 

Sivifene 2675-35-6 

Sodelglitazar 447406-78-2 

Sofigatran 187602-11-5 

Sontuzumab 372075-37-1 

Sotirimod 227318-75-4 

Sotrastaurin 425637-18-9 

Stamulumab 705287-60-1 

Succinobucol 216167-82-7 

Tadocizumab 339086-80-5 

Talarozole 870093-23-5 

Talmapimod 309913-83-5 

Talotrexin 113857-87-7 

Tanespimycin 75747-14-7 

Tanezumab 880266-57-9 

Taranabant 701977-09-5 

Tarenflurbil 051543-40-9 

Taribavirin 119567-79-2 

Tasimelteon 609799-22-6 

Tasisulam 519055-62-0 

Taspoglutide 275371-94-3 

Tecovirimat 816458-31-8 

Telaprevir 402957-28-2 

A-12
Telatinib 332012-40-5 

Tenatumomab (light chain) 592557-43-2 

Tenatumomab (heavy chain) 592557-41-0 

Teneligliptin 760937-92-6 

Teplizumab 876387-05-2 

Terameprocol 24150-24-1 

Tertomotide 915019-08-8 

Tesamorelin 218949-48-5 

Tezampanel 154652-83-2 

Thrombin Alfa 869858-13-9 

Ticagrelor 274693-27-5 

Tigapotide 848084-83-3 

Tigatuzumab 918127-53-4 

Tildipirosin 328898-40-4 

Tipelukast 125961-82-2 

Tiplasinin 393105-53-8 

Tomopenem 222400-20-6 

Tosedostat 238750-77-1 

Totrombopag 376592-42-6 

Trabedersen 925681-61-4 

Tramiprosate 3687-18-1 

Transferrin Aldifitox 721946-42-5 

Trelanserin 189003-92-7 

Tremelimumab 745013-59-6 

Tridecactide 22006-64-0 

Tropantiol 189950-11-6 

Troplasminogen Alfa 931101-84-7 

Tucotuzumab Celmoleukin 339986-90-2 

Tylvalosin 63409-12-1 

Ustekinumab 815610-63-0 

Vabicaserin 620948-93-8 

Vadimezan 117570-53-3 

Vapitadine 793655-64-8 

Vatreptacog Alfa (Activated) 897936-89-9 

Velafermin 697766-75-9 

Velaglucerase Alfa 884604-91-5 

Veliflapon 128253-31-6 

Velimogene Aliplasmid 296251-72-4 

Velneperit 342577-38-2 

Veltuzumab 728917-18-8 

Vernakalant 794466-70-9 

Verpasep Caltespen 295371-00-5 

A-13
Vicriviroc 306296-47-9 

Viquidacin 904302-98-3 

Voclosporin 515814-01-4 

Volinaserin 139290-65-6 

Vorinostat 149647-78-9 

Votucalis 872525-61-6 

Zibotentan 186497-07-4 

Zotarolimus 221877-54-9 

A-14
Table 2 

Prefixes and suffixes proposed for addition to the Pharmaceutical Appendix to the Harmonized 

Tariff Schedule 

Item 

alanetil 

alaninate 

dldfJlVUxil 

ceribate -~-~ 

cipecilate 

dalanated --

enacarbil ----- -~ 

etexilate -~ 

fosamil 

glucuronide 

.:1 III':;UVvalli 

,:I 

I-'IC'VOIUII 

aldifitox 

aritox 

hA"-' ,r\ntn'\{ 

c",aIClla'UA 

paptox 

A-15
Table 3 

Pharmaceutical intermediates proposed for addition to the Pharmaceutical Appendix to the Harmonized 

Tariff Schedule of the United States 

Product Name CAS Number 

(2R)-phenyl[(2R)-piperidin-2-yl]ethanoic acid hydrochloride 741705-70-4 

methyl (1S,2S,3S,4R)-3-[(1S)-1-amino-2-ethylbutyl]-4-[(tert-butoxycarbonyl)amino]-2-

hydroxycyclopentanecarboxylate 316173-29-2 

disodium 5,5'-[(2-hydroxypropane-1,3-diyl)bis(oxy)]bis(4-oxo-4H-chromene-2-carboxylate) 15826-37-6 

N,N',N''-(boroxin-2,4,6-triyltris{[(1S)-3-methylbutane-1,1-diyl]imino[(2S)-1-oxo-3-phenylpropane1,2-diyl]})tripyrazine-2-carboxamide 390800-88-1 

1-(2-ethylbutyl)cyclohexanecarbonyl chloride 211515-46-7 

1-(2-ethylbutyl)-N-(2-sulfanylphenyl)cyclohexanecarboxamide 211513-21-2 

ethyl 2-amino-9,10-dimethoxy-1,6,7,11b-tetrahydro-4H-pyrido[2,1-a]isoquinoline-3-carboxylate 1012065-72-3 

3-(1,1-dimethylethyl)-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-1-(triphenylmethyl)-L-histidyl-2-

methylalanyl-L-α-glutamylglycine 1000164-35-1 

N-(4-tert-butylbenzyl)-2-(4-chloro-3-ethylphenyl)ethanamine 945717-43-1 

2-(4-chloro-3-ethylphenyl)ethanamine hydrochloride 945717-05-5 

ethyl (3aR,7R,7aR)-2,2-dimethyl-7-[(methylsulfonyl)oxy]-3a,6,7,7a-tetrahydro-1,3-

benzodioxole-5-carboxylate 204254-84-2 

(2R,3R,4R,5R)-2-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-2-fluoro-5-methyltetrahydrofuran3,4-diyl diacetate 161599-46-8 

(2R,3S,4R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-azido-2-{[(2-

methylpropanoyl)oxy]methyl}tetrahydrofuran-3,4-diyl bis(2-methylpropanoate) hydrochloride 690270-65-6 

{(2R,3S,4R,5R)-2-azido-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-

bis[(phenylcarbonyl)oxy]tetrahydrofuran-2-yl}methyl 3-chlorobenzoate 812647-80-6 

1-(2-ethylbutyl)cyclohexanecarboxylic acid 381209-09-2 

1-(2-ethylbutyl)cyclohexanecarbonitrile 855425-38-6 

(4S)-1-[(2S,3S,11bS)-2-amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-

a]isoquinolin-3-yl]-4-(fluoromethyl)pyrrolidin-2-one dihydrochloride 813452-14-1 

(4S)-4-(fluoromethyl)dihydrofuran-2(3H)-one 916069-80-2 

2-[4-(aminomethyl)phenoxy]-N,N-dimethylethanamine 20059-73-8 

trans-4-(propan-2-yl)cyclohexanecarboxylic acid 7077-05-6 

(3β)-3-hydroxycholest-5-en-24-one 17752-16-8 

3-ethyl-5-methyl-4-(2-chlorophenyl)-2-{[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-

yl)ethoxy]methyl}-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate 88150-62-3 

(1S)-1,5:7,10-dianhydro-12,13-bis-O-[tert-butyl(dimethyl)silyl]-2,3,4,6,8,11-hexadeoxy-1-{2-

[(2S,5S)-5-(3-hydroxypropyl)-3-methylidenetetrahydrofuran-2-yl]ethyl}-3-methyl-9-O-methyl-4-

methylidene-8-[(phenylsulfonyl)methyl]-D-arabino-D-altro-tridecitol 

253128-10-8 

(2R,4R)-4-{[tert-butyl(dimethyl)silyl]oxy}-N-methoxy-N,2-dimethyloct-7-enamide 914922-88-6 

A-16
(4R)-2-bromo-7-{[tert-butyl(diphenyl)silyl]oxy}hept-1-en-4-yl 4-methylbenzenesulfonate 871355-80-5 

(2R,4R)-4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-N-methoxy-N,2-dimethyl-7-oxoheptanamide 914922-89-7 

(2-bromoethenyl)(trimethyl)silane 13682-94-5 

methyl 3-(trimethylsilyl)pent-4-enoate 185411-12-5 

1-{[(2R,3S)-2-(2,4-difluorophenyl)-3-methyloxiran-2-yl]methyl}-1H-1,2,4-triazole 127000-90-2 

4-(bromoacetyl)benzonitrile 20099-89-2 

(3R)-3-methoxydecan-1-ol 185954-75-0 

2-(1,3,2-dioxaborinan-2-yl)benzonitrile 172732-52-4 

4,5-diethoxy-3-fluorobenzene-1,2-dicarbonitrile 474554-45-5 

2-bromo-1-[3-tert-butyl-4-methoxy-5-(morpholin-4-yl)phenyl]ethanone 474554-48-8 

L-lysine -- {[(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1H-1,2,4-

triazol-1-yl)butan-2-yl]oxy}methyl dihydrogen phosphate -- ethanol (1:1:1) 914361-45-8 

4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide 

methanesulfonate 417716-92-8 

2-[({4-[(2,2-dimethyl-1,3-dioxan-5-yl)methoxy]-3,5-dimethylpyridin-2-yl}methyl)sulfinyl]-

1Hbenzimidazole, sodium salt (1:1) 913695-00-8 

(1R)-1,2-anhydro-4-C-{(1E,3E)-4-[(1S,2S,3E,5R,6R,9R)-5-(1-carboxylato-4-

cycloheptylpiperazin-2-yl)-6,9-dihydroxy-2,6-dimethyl-11-oxooxacyclododec-3-en-1-yl]penta1,3-dien-1-yl}-3,5-dideoxy-1-[(2R,3S)-3-hydroxypentan-2-yl]-D-erythropentitol 630100-90-2 

[6(2Z,3R)]-3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-(3-metoxydecyl)-6-methyl-2-[(1-oxo-11-

octadecenyl)amino]-4-O-phosphono-β-D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-α-Dglucopyranose 1-(dihydrogen phosphate) tetrasodium salt 

185954-98-7 

2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl methanesulfonate 160969-03-9 

3-{5-[(2R)-2-aminopropyl]-7-cyano-2,3-dihydro-1H-indol-1-yl}propyl benzoate (2R,3R)-2,3-

dihydroxybutanedioate 239463-85-5 

4,6,7,8-tetrahydroquinoline-2,5(1H,3H)-dione 5057-12-5 

5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole 73963-42-5 

6-hydroxy-3,4-dihydroquinolin-2(1H)-one 54197-66-9 

8,9-difluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid 80076-47-7 

7-hydroxy-3,4-dihydroquinolin-2(1H)-one 22246-18-0 

4-chlorobutyl 2-nitrobenzenesulfonate 441002-17-1 

3-(2-oxo-1,2-dihydroquinolin-4-yl)alanine 5162-90-3 

4-(bromomethyl)quinolin-2(1H)-one 4876-10-2 

1-[(4-methylphenyl)sulfonyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one 24310-36-9 

A-17
4-{[(2-methylphenyl)carbonyl]amino}benzoic acid 108166-22-9 

2-methyl-4-{[(2-methylphenyl)carbonyl]amino}benzoic acid 317374-08-6 

7-chloro-1-[(4-methylphenyl)sulfonyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one 193686-76-9 

6-(chloroacetyl)pyridine-2-carboxylic acid 298692-34-9 

3,4-diethoxybenzenecarbothioamide 60759-00-4 

4-{4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl}phenol 4-methylbenzenesulfonate 866109-93-5 

[(2R)-2-methyloxiran-2-yl]methyl 4-nitrobenzenesulfonate 683276-64-4 

2-bromo-4-nitro-1H-imidazole 65902-59-2 

2-chloro-4-nitro-1H-imidazole 57531-37-0 

4-nitrobenzyl(6R,7R)-7-amino-8-oxo-3-[(2S)-tetrahydrofuran-2-yl]-5-thia-1-azabicyclo[4.2.0]oct2-ene-2-carboxylate hydrochloride 655233-39-3 

[4-amino-N-(pyrimidin-2(1H)-ylidene-κN1)benzenesulfonamidato-κO]silver 22199-08-2 

2-[2-(3-methoxyphenyl)ethyl]phenol 167145-13-3 

N-{[4-(4-fluorobenzyl)morpholin-2-yl]methyl}acetamide 112913-94-7 

{2-[(4-chlorophenyl)sulfanyl]phenyl}acetic acid 13459-62-6 

N-cyclohexyl-5-hydroxypentanamide 84996-93-0 

4-chloro-2-[(2-methoxy-2-oxoethoxy)imino]-3-oxobutanoic acid 95759-10-7 

tert-butyl-2-[(2-methoxy-2-oxoethoxy)imino]-3-oxobutanoate 268544-50-9 

tert-butyl (2Z)-2-[(2-methoxy-2-oxoethoxy)imino]-3-oxobutanoate 84080-68-2 

sodium (2Z)-(2-amino-1,3-thiazol-4-yl)(hydroxyimino)ethanoate 127660-04-2 

diphenylmethyl(2R)-3-methyl-2-[(1R,5S)-3-(4-methylphenyl)-7-oxo-4-oxa-2,6-

diazabicyclo[3.2.0]hept-2-en-6-yl]but-3-enoate 67978-05-6 

4-(hydroxymethyl)-5-methyl-1,3-dioxol-2-one 91526-18-0 

2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethanamine hydrochloride 196597-80-5 

(2E)-1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-ylideneethanenitrile 196597-79-2 

methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate 139481-44-0 

methyl 2-{[(2'-cyanobiphenyl-4-yl)methyl]amino}-3-nitrobenzoate 139481-28-0 

2-[(6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]benzonitrile 865758-96-9 

(3R)-piperidin-3-amine dihydrochloride 334618-23-4 

iodomethyl pivalate 53064-79-2 

A-18
ethyl 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-

naphthyridine-3-carboxylate 105152-95-2 

4-(1-carbamoylcyclopropyl)-2,3,5-trifluorobenzoic acid 143785-84-6 

(3S)-10-[1-(acetylamino)cyclopropyl]-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-

[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid 163680-80-6 

(6R,7R)-7-({N-[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]-D-threonyl}amino)-3-{[(1-methyl-1Htetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 76610-92-9 

N-(5-methoxy-2-phenoxyphenyl)methanesulfonamide 123664-84-6 

N-[4-(N-formylglycyl)-5-methoxy-2-phenoxyphenyl]methanesulfonamide 149456-98-4 

N-[4-(N-formylglycyl)-5-hydroxy-2-phenoxyphenyl]methanesulfonamide 149457-03-4 

5-bromo-1-benzothiophene 4923-87-9 

(1-benzothiophen-5-yl)acetic acid 17381-54-3 

2-(1-benzothiophen-5-yl)ethanol 96803-30-4 

3-[2-(1-benzothiophen-5-yl)ethoxy]propionic acid 519188-42-2 

3-[2-(1-benzothiophen-5-yl)ethoxy]-1-(3-hydroxyazetidin-1-yl)propan-1-one 519188-55-7 

1-[3-(2-benzo[b]thien-5-ylethoxy)propyl]-3-azetidinol -- (2Z)-2-butenedioate (1:1) 519187-97-4 

2-oxo-2H-chromene-6-carboxylic acid 7734-80-7 

6-[(2,4-dimethoxyphenyl)carbonyl]-2H-chromen-2-one 947408-90-4 

6-[(2,4-dihydroxyphenyl)carbonyl]-2H-chromen-2-one 947408-91-5 

methyl 3-(5-{[4-(cyclopentyloxy)-2-hydroxyphenyl]carbonyl}-2-hydroxyphenyl)propanoate 530141-60-7 

N,2-dihydroxy-4-methylbenzamide 158671-29-5 

6-methyl-2-trityl-1,2-benzoxazol-3(2H)-one 947408-94-8 

6-(bromomethyl)-2-triphenylmethyl-1,2-benzisoxazol-3(2H)-one 947408-95-9 

methyl 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(2-triphenylmethyl-1,2-benzisoxazol3(2H)-on6-yl)methoxy]phenyl]propionate 

947409-01-0 

3-(5-{[4-(cyclopentyloxy)-2-hydroxyphenyl]carbonyl}-2-[(3-hydroxy-1,2-benzoxazol-6-

yl)methoxy]phenyl)propanoic acid 530141-72-1 

2-aminomalonamide 62009-47-6 

3-oxo-3,4-dihydropyrazine-2-carboxamide 55321-99-8 

6-bromo-3-oxo-3,4-dihydropyrazine-2-carboxamide 259793-88-9 

3-oxo-4-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-3,4-dihydropyrazine-2-carboxamide 499785-81-8 

3-oxo-4-(β-D-ribofuranosyl)-3,4-dihydropyrazine-2-carboxamide 356782-84-8 

A-19
3,3'-piperidine-1,4-diyldipropan-1-ol 4-methylbenzenesulfonate 936637-40-0 

4,4'-[piperidine-1,4-diylbis(propane-3,1-diyloxy)]dibenzonitrile 873546-80-6 

4,4'-[piperidine-1,4-diylbis(propane-3,1-diyloxy)]bis(N'-hydroxybenzenecarboximidamide) 873546-30-6 

4,4'-[piperidine-1,4-diylbis(propane-3,1-diyloxy)]bis[N'-(acetyloxy)benzenecarboximidamide] 873546-74-8 

4,4'-[piperidine-1,4-diylbis(propane-3,1-diyloxy)]dibenzenecarboximidamide trihydrochloride 

pentahydrate 873546-38-4 

benzyl 2-(4-fluoro-2-methylphenyl)-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate 414909-98-1 

(1R)-1-[3,5-bis(trifluoromethyl)phenyl]-N-methylethanamine 334477-60-0 

(2S)-hydroxy(phenyl)ethanoic acid -- (2R)-2-(4-fluoro-2-methylphenyl)piperidin-4-one (1:1) 414910-13-7 

ethyl [(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl)acetate 56880-11-6 

(1R)-2-(benzylamino)-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol 452342-08-4 

(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one 452339-73-0 

2-[(2,6-dichlorobenzyl)oxy]ethanol 85309-91-7 

2-({2-[(6-bromohexyl)oxy]ethoxy}methyl)-1,3-dichlorobenzene 503070-57-3 

(5R)-3-(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-

1,3-oxazolidin-2-one 503068-36-8 

triphenylacetic acid -- 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-

hydroxyethyl}-2-(hydroxymethyl)phenol (1:1) 503070-58-4 

5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-

furancarboxaldehyde 4-methylbenzenesulfonate (1:1) 388082-75-5 

1,2,3,4,6-penta-O-acetyl-β-D-glucopyranose 604-69-3 

methyl 3'-aminobiphenyl-3-carboxylate 168619-25-8 

N-(2-chloroethyl)acetamide 7355-58-0 

methyl 3'-(2-methyl-4,5-dihydro-1H-imidazol-1-yl)biphenyl-3-carboxylate 451470-33-0 

(2R)-2-(3-chlorophenyl)oxirane 62600-71-9 

N-methylbenzenecarbothiohydrazide 21048-05-5 

1-{[(methylsulfanyl)carbonyl]oxy}ethyl 2-methylpropanoate 860035-07-0 

1-({[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl}oxy)ethyl 2-methylpropanoate 860035-10-5 

[(3S,4R)-4-(4-fluorophenyl)-1-methylpiperidin-3-yl]methanol 105812-81-5 

(2R)-2-[(5-bromo-2,3-difluorophenoxy)methyl]oxirane 702687-42-1 

ethyl 3-(3-{[(2R)-3-{[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino}-2-

hydroxypropyl]oxy}-4,5-difluorophenyl)propanoate hydrochloride 702686-97-3 

(4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione 7689-03-4 

A-20
9H-carbazol-4-ol 52602-39-8 

2-[(4-fluorobenzyl)sulfanyl]-1,5,6,7-tetrahydro-4H-cyclopenta[d]pyrimidin-4-one 451487-18-6 

{2-[(4-fluorobenzyl)sulfanyl]-4-oxo-4,5,6,7-tetrahydro-1H-cyclopenta[d]pyrimidin-1-yl}acetic acid 356058-42-9 

4'-(trifluoromethyl)biphenyl-4-carbaldehyde 90035-34-0 

(5-chloro-2-methoxyphenyl)boronic acid 89694-48-4 

5'-chloro-2'-hydroxy-3'-nitrobiphenyl-3-carboxylic acid 376592-58-4 

2-(3,4-dimethylphenyl)-5-methyl-2,4-dihydro-3H-pyrazol-3-one 18048-64-1 

2,3-dimethyl-2H-indazol-6-amine 444731-72-0 

2,4-dichloropyrimidine 3934-20-1 

N-(2-chloropyrimidin-4-yl)-2,3-dimethyl-2H-indazol-6-amine 444731-74-2 

5-amino-2-methylbenzenesulfonamide 6973-09-7 

2-[methyl(pyridin-2-yl)amino]ethanol 122321-04-4 

(5Z)-5-(4-fluorobenzylidene)-1,3-thiazolidine-2,4-dione 291536-35-1 

1,6-di-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-D-glucopyranose 136172-58-2 

methyl 6-O-acetyl-4-O-(2-O-acetyl-3-O-benzyl-6-methyl-α-L-idopyranuronosyl)-3-O-benzyl-2-

{[(benzyloxy)carbonyl]amino}-2-deoxy-α-D-glucopyranoside 114869-97-5 

methyl (2S,3S,4S,5S,6S)-6-{[(1S,2S,3S,4R,5R)-3-(acetyloxy)-4-azido-6,8-

dioxabicyclo[3.2.1]oct-2-yl]methyl}-4,5-bis(benzyloxy)-3-hydroxytetrahydro-2H-pyran-2-

carboxylate 

99541-26-1 

(1R,2S,3R,4R,5R)-4-azido-2-{[(4aR,6S,7R,8S,8aR)-7,8-bis(benzyloxy)-2-

phenylhexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy}-6,8-dioxabicyclo[3.2.1]oct-3-yl acetate 99541-23-8 

4-[3-hydroxy-3-phenyl-3-(thiophen-2-yl)propyl]-4-methylmorpholin-4-ium methyl sulfate 6504-57-0 

methyl 3-amino-4-methylthiophene-2-carboxylate 85006-31-1 

4-cyclopentylpiperazin-1-amine 61379-64-4 

4-methylpiperazine-1-carbonyl chloride hydrochloride 55112-42-0 

5-chloropyridin-2-amine 1072-98-6 

2-chlorobenzylamine 89-97-4 

benzyl (2S,3aR,7aS)-octahydro-1H-indole-2-carboxylate hydrochloride 145641-35-6 

6-chlorohexan-2-one 10226-30-9 

ethyl 3-[(5-chloro-2-nitrophenyl)(phenyl)amino]-3-oxopropanoate 22316-45-6 

colchicoside 477-29-2 

(3β,16α)-3-hydroxy-16,17-epoxypregn-5-en-20-one 974-23-2 

A-21
antimonic acid -- 1-deoxy-1-(methylamino)-D-glucitol (1:1) 133-51-7 

sodium hydrogen 3-sulfonatobenzoate 17625-03-5 

ethyl 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoate 52179-28-9 

sodium 2-propylpentanoate 1069-66-5 

propyl {4-[2-(diethylamino)-2-oxoethoxy]-3-ethoxyphenyl}acetate 579494-66-9 

5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole6-carboxamide 606143-52-6 

4-hydroxybenzoic acid -- (2S,4E)-N-methyl-5-[5-(propan-2-yloxy)pyridin-3-yl]pent-4-en-2-amine 

(1:1) 691882-47-0 

N-(2-{[(2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methylpropyl]oxy}-4-

hydroxyphenyl)acetamide 548797-97-3 

4-amino-8-(2,5-dimethoxyphenyl)-N-propylcinnoline-3-carboxamide 942436-93-3 

4-amino-8-(2-fluoro-6-methoxyphenyl)-N-propylcinnoline-3-carboxamide 942437-37-8 

(2S)-1-(tert-butoxycarbonyl)azetidine-2-carboxylic acid 51077-14-6 

(2S)-N-{4-[(Z)-amino(methoxyimino)methyl]benzyl}-1-{(2R)-2-[3-chloro-5-

(difluoromethoxy)phenyl]-2-hydroxyethanoyl}azetidine-2-carboxamide benzenesulphonic acid 

(1:1) 

631916-97-7 

2-{ethyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-

yl}oxy)propyl]amino}ethyl dihydrogen phosphate 722543-31-9 

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran4-yl)oxy]-4-quinazolinamine -- (2E)-2-butenedioate (1:2) 893428-72-3 

3-[(methylsulfonyl)amino]-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide 941690-55-7 

(2R)-3'H-spiro[4-azabicyclo[2.2.2]octane-2,2'-furo[2,3-b]pyridine] (S,S)-2,3-

dihydroxybutanedioate 220100-81-2 

(2R)-3'H-spiro[4-azabicyclo[2.2.2]octane-2,2'-furo[2,3-b]pyridine] 220099-91-2 

4-fluoro-2-methyl-1H-indol-5-ol 288385-88-6 

2-{[(3aR,4S,6R,6aS)-6-{[5-amino-6-chloro-2-(propylsulfanyl)pyrimidin-4-yl]amino}-2,2-

dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy}ethanol 376608-74-1 

(1R,2S)-2-(3,4-difluorophenyl)cyclopropanaminium (2R)-hydroxy(phenyl)ethanoate 376608-71-8 

7-(benzyloxy)-6-methoxyquinazolin-4(3H)-one 179688-01-8 

sodium hydrogen [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonate hemipentahydrate 329003-65-8 

(5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,35S,38S)-5-(3-amino-3-oxopropyl)-20-benzyl-23-

[(2S)-butan-2-yl]-14,38-bis{4-[(tert-butoxycarbonyl)amino]butyl}-29-{[1-(tert-butoxycarbonyl)-1Hindol-3-yl]methyl}-17-(3-tert-butoxy-3-oxopropyl)-1-(1H-fluoren-9-yl)-8,11,26,41,41-

pentamethyl-32-(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33,36,39-tridecaoxo-35-(propan2-yl)-2-oxa-4,7,10,13,16,19,22,25,28,31,34,37,40-tridecaazadotetracontan-42-oic acid 

1000164-36-2 

5-methyl-1-(propan-2-yl)-4-[4-(propan-2-yloxy)benzyl]-1,2-dihydro-3H-pyrazol-3-one 1028026-83-6 

2-methyl-3-[(2S)-pyrrolidin-2-ylmethoxy]pyridine 2,3-dihydroxybutanedioate 945405-37-8 

A-22
(2S,3S)-2,3-bis[(phenylcarbonyl)oxy]butanedioic acid -- ethyl (3aR,6aR)-hexahydropyrrolo[3,4-

b]pyrrole-5(1H)-carboxylate (1:1) 948846-40-0 

(3aR,6aR)-1-(pyridin-3-yl)octahydropyrrolo[3,4-b]pyrrole 4-methylbenzenesulfonate 00-00-0 

(3aR,6aR)-1-(pyridin-3-yl)octahydropyrrolo[3,4-b]pyrrole dihydrochloride 370882-57-8 

4-[(3-nitropyridin-2-yl)amino]phenol 78750-61-5 

1-(2-fluoro-5-methylphenyl)-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]urea 796967-18-5 

N-{2-[(4-hydroxyphenyl)amino]pyridin-3-yl}-4-methoxybenzenesulfonamide hydrochloride 141450-48-8 

1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea hydrochloride 00-00-0 

1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea 796967-16-3 

5,6-dichloro-N-(2,2-dimethoxyethyl)pyridin-3-amine 876068-46-1 

[(3S,4S)-4-amino-1-(5,6-dichloropyridin-3-yl)pyrrolidin-3-yl]methanol 876068-51-8 

(1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate 876170-44-4 

DNA, d(T-sp-C-G-sp-T-sp-C-G-sp-T-sp-T-sp-T-sp-T-sp-G-sp-A-sp-C-G-sp-T-sp-T-sp-T-sp-Tsp-Gsp-T-sp-C-G-sp-T-sp-T) 665058-78-6 

4-(4-{[(2S,4R)-4-[acetyl(4-chlorophenyl)amino]-2-methyl-3,4-dihydroquinolin-1(2H)-

yl]carbonyl}phenoxy)-2,2-dimethylbutanoic acid 868210-14-4 

4-[4-({3-[(4-deoxy-4-fluoro-b-D-glucopyranosyl)oxy]-5-(propan-2-yl)-1H-pyrazol-4-

yl}methyl)phenyl]-N-[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]butanamide 871484-32-1 

2-({[(1R,3S)-3-{[2-(3-methoxyphenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}cyclohexyl]oxy}methyl)-

6-methylbenzoic acid 710281-33-7 

2-(4-methoxybenzyl)thiophen-3-yl β-D-glucopyranoside 647834-15-9 

5-(benzylamino)-2-(3-methoxyphenyl)-7-(4-methylpiperazin-1-yl)[1,2,4]triazolo[1,5-a]quinoline4-carbonitrile -- (2E)-but-2-enedioate (2:1) hydrate 00-00-0 

3-[2-chloro-4-({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methoxy)phenyl]-1,2,4-

oxadiazol-5(4H)-one 866920-24-3 

2-[3-(6-{[2-(2,4-dichlorophenyl)ethyl]amino}-2-methoxypyrimidin-4-yl)phenyl]-2-methylpropanoic 

acid phosphate 934815-71-1 

(2Z)-[(acetyloxy)imino](2-amino-1,3-thiazol-4-yl)ethanoic acid 110130-88-6 

2-(2,3-dihydro-1H-inden-2-yl)propan-2-amine hydrochloride 1034457-07-2 

(2R)-1-(5-bromo-2,3-difluorophenoxy)-3-{[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2- 

yl]amino}propan-2-ol hydrochloride 1035455-90-3 

ethyl (2E)-3-(3-{[(2R)-3-{[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino}-2-

hydroxypropyl]oxy}-4,5-difluorophenyl)prop-2-enoate hydrochloride 1035455-87-8 

(3S,6R,9S,12R,15S,18R,21S,24R)-6,18-dibenzyl-4,10,12,16,22,24-hexamethyl-3,9,15,21-

tetrakis(2-methylpropyl)-1,7,13,19-tetraoxa-4,10,16,22-tetraazacyclotetracosane2,5,8,11,14,17,20,23-octone 

133413-70-4 

2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-

sulfonamide di[(2E)-but-2-enedioate] hydrate 00-00-0 

A-23
5-fluoro-1-(3-fluorobenzyl)-N-(1H-indol-5-yl)-1H-indole-2-carboxamide 00-00-0 

(+)-5-[6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl]-1-azabicyclo[3.2.1]octane 925978-49-0 

7-chloro-3-(6-methoxypyridin-3-yl)-N,N,5-trimethyl-4-oxo-4,5-dihydro-3H-pyridazino[4,5-

b]indole-1-carboxamide 550349-58-1 

N-[(S)-1-azabicyclo[2.2.2]oct-2-yl(phenyl)methyl]-2,6-dichloro-3-(trifluoromethyl)benzamide 

hydrochloride 00-00-0 

4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-

5-methyl-N-(prop-2-yn-1-yl)-1,3-thiazol-2-amine 752253-39-7 

2-amino-2-oxoethyl{3-[trans-5-(6-methoxynaphthalen-1-yl)-1,3-dioxan-2-yl]propyl}carbamate 666860-59-9 

N-(5-fluoro-3-methyl-1H-indol-1-yl)-4-methyl-2-(pyridin-2-yl)pyrimidine-5-carboxamide 00-00-0 

DNA (synthetic plasmid vector pCOR human interferon b signal peptide fusion protein with 21-

154-human acidic fibroblast growth factor-specifying) 1001859-46-6 

1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione -- 1-

methylpyrrolidin-2-one (1:1) 165172-60-1 

[(1R,5S)-5-[dimethyl(phenyl)silyl]-2-{[(2-methoxypropan-2-yl)oxy]methyl}cyclopent-2-en-1-

yl]methanol 701278-08-2 

{(4S,5R)-5-[(benzyloxy)methyl]-4-[dimethyl(phenyl)silyl]cyclopent-1-en-1-yl}methanol 701278-09-3 

2-amino-9-{(1S,3R,4S)-3-[(benzyloxy)methyl]-4-[dimethyl(phenyl)silyl]-2-

methylidenecyclopentyl}-1,9-dihydro-6H-purin-6-one methanesulfonate (2:1) 1032066-96-8 

2-amino-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide 302964-24-5 

N-(2-chloro-6-methylphenyl)-2-[(6-chloro-2-methylpyrimidin-4-yl)amino]-1,3-thiazole-5-

carboxamide 302964-08-5 

4,6-dichloro-2-methylpyrimidine 1780-26-3 

tert-butyl [(1S)-2-[(1S,3S,5S)-3-cyano-2-azabicyclo[3.1.0]hex-2-yl]-1-(3-

hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)-2-oxoethyl]carbamate 709031-43-6 

{2-[(tert-butoxycarbonyl)amino]-3-hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl}acetic acid 361442-00-4 

(1S,3S,5S)-2-azabicyclo[3.1.0]hexane-3-carboxamide methanesulfonate 709031-45-8 

(3-hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)(oxo)acetic acid 709031-28-7 

tert-butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate 361440-67-7 

tert-butyl (2S)-2-carbamoyl-2,3-dihydro-1H-pyrrole-1-carboxylate 709031-38-9 

5-methyl-4-oxo-1,4-dihydropyrrolo[2,1-f][1,2,4]triazin-6-yl 2,2-dimethylpropanoate 872206-47-8 

4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl 2,2-

dimethylpropanoate 952490-01-6 

(2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-

yl}oxy)propan-2-ol 649735-46-6 

(2R)-2-methyloxirane 15448-47-2 

N-benzyloxycarbonyl-L-alanine 1142-20-7 

A-24
ethyl 1-(4-methoxyphenyl)-6-(4-nitrophenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-

c]pyridine-3-carboxylate 536759-91-8 

ethyl 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1Hpyrazolo[3,4-c]pyridine-3-carboxylate 503614-91-3 

ethyl (2Z)-chloro[2-(4-methoxyphenyl)hydrazinylidene]ethanoate 473927-63-8 

3-chloro-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one 536760-29-9 

4-(5-bromo-2-chlorobenzyl)phenyl ethyl ether 461432-23-5 

but-2-yne-1,4-diol -- methyl 1-C-[4-chloro-3-(4-ethoxybenzyl)phenyl]-α-D-glucopyranoside (1:1) 960404-59-5 

(1S)-2,3,4,6-tetra-O-acetyl-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol 461432-25-7 

N-{5-[(diphenylphosphoryl)methyl]-4-(4-fluorophenyl)-6-(propan-2-yl)pyrimidin-2-yl}-Nmethylmethanesulfonamide 289042-10-0 

(3-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(2-fluorophenyl)morpholin-4-

yl]methyl}-5-oxo-2,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid -- 1-deoxy-1-(methylamino)-

D-glucitol (1:2) 

265121-04-8 

methyl 1-tert-butyl-2-hydroxy-1H-pyrrolo[2,3-b]pyridine-3-carboxylate 00-00-0 

[(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]acetic acid 957187-34-7 

2,3-dihydroxy-2,3-bis(phenylcarbonyl)butanedioic acid -- ethyl [(8R)-8-(3,5-difluorophenyl)-10-

oxo-6,9-diazaspiro[4.5]dec-9-yl]acetate (1:1) 00-00-0 

2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethanone 893407-18-6 

[2-(chloromethyl)-4-(dibenzylamino)phenyl]methanol hydrochloride 00-00-0 

4-fluoro-L-leucine -- ethyl hydrogen sulfate (1:1) 848949-85-9 

4-(4-fluorophenyl)-7-(isothiocyanatomethyl)-2H-chromen-2-one 00-00-0 

3-{[6-(ethylsulfonyl)pyridin-3-yl]oxy}-5-{[(2S)-1-hydroxypropan-2-yl]oxy}benzoic acid -- 1,4-

diazabicyclo[2.2.2]octane (2:1) 1137917-12-4 

methyl (5R,7S,10S)-10-tert-butyl-15,15-dimethyl-3,9,12-trioxo6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-

benzodioxatriazacyclohenicosine-7(3H)-carboxylate 

923591-06-4 

(1R,2R)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethylcyclopropanaminium 4-

methylbenzenesulfonate 1198178-65-2 

2-hydroxy-2-(trifluoromethyl)butanehydrazide 910656-45-0 

4-(ethylamino)piperidine-4-carboxamide 84100-54-9 

6-(hydroxymethyl)-4-phenyl-3,4-dihydro-2H-chromen-2-ol 959624-24-9 

3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-

oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate 540737-29-9 

2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine 90213-66-4 

1-({4-[({[2-oxo-3-(propan-2-yl)-2,3-dihydro-1H-benzimidazol-1-

yl]carbonyl}amino)methyl]piperidin-1-yl}methyl)cyclobutanecarboxylic acid 871022-14-9 

A-25
1-[(4-{[(tert-butoxycarbonyl)amino]methyl}piperidin-1-yl)methyl]cyclobutanecarboxylic acid 871022-19-4 

1-(propan-2-yl)-1,3-dihydro-2H-benzimidazol-2-one 35681-40-4 

S-[(1R,3S)-1-oxidotetrahydrothiophen-3-yl] ethanethioate 120788-03-6 

2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole 3613-73-8 

2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole 19686-05-6 

(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile 941678-49-5 

3-cyclopentylprop-2-enenitrile 591769-05-0 

1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 1029716-44-6 

4-(1H-pyrazol-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine 941685-27-4 

(3S)-3-cyclopentyl-3-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1Hpyrazol-1-yl]propanenitrile 941685-41-2 

(3R)-3-cyclopentyl-3-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1Hpyrazol-1-yl]propanenitrile 941685-40-1 

3-cyclopentyl-3-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1Hpyrazol-1-yl]propanenitrile 941685-39-8 

4-chloro-7H-pyrrolo[2,3-d]pyrimidine 3680-69-1 

(3S,5R)-3-amino-5-methyloctanoic acid hydrochloride 610300-00-0 

(3S,5R)-3-amino-5-methyloctanoic acid 610300-07-7 

(3R)-3-methylhexanoic acid 22328-90-1 

(2R,3R)-2,3-dimethylbutane-1,4-diyl bis(4-methylbenzenesulfonate) 281214-27-5 

4-(1-aminocyclopropyl)-2,3,5-trifluorobenzoic acid 143785-86-8 

4-[1-(acetylamino)cyclopropyl]-2,3,5-trifluorobenzoic acid 143785-87-9 

(6R)-6-cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-

a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one 877130-28-4 

5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde 55293-96-4 

4-bromo-2,6-diethylpyridine 4-methylbenzenesulfonate 927889-51-8 

sodium 2-amino-2-phenylbutanoate 94133-84-3 

methyl 2-(dimethylamino)-2-phenylbutanoate 39068-93-4 

3-(4-chlorophenyl)-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide 1035675-24-1 

(4S)-3-(4-chlorophenyl)-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide 2,3-

dihydroxybutanedioate 1035677-60-1 

(3,3-difluoropyrrolidin-1-yl){(2S,4S)-4-[4-(pyrimidin-2-yl)piperazin-1-yl]pyrrolidin-2-yl}methanone 869490-23-3 

3,3-difluoropyrrolidine hydrochloride 163457-23-6 

A-26
6-iodo-1H-indazole 261953-36-0 

(-)-3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl}-N,4-

dimethylbenzamide 586414-48-4 

methyl 3-(4-hydroxy-6-methyl-2-oxopyridin-1(2H)-yl)-4-methylbenzoate 586379-61-5 

(1S)-1-amino-3-methyl-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one hydrochloride 425663-71-4 

L-α-aspartyl-L-α-glutamyl-L-asparaginyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-phenylalanyl-Lphenylalanyl-L-lysyl-L-asparaginyl-L-isoleucyl-L-valyl-L-threonyl-L-prolyl-L-arginyl-L-threonine 152074-97-0 

L-α-aspartyl-L-α-glutamyl-L-asparaginyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-phenylalanyl-Lphenylalanyl-L-lysyl-L-asparaginyl-L-isoleucyl-L-valyl-L-threonyl-L-prolyl-L-arginyl-L-threonine 

tetraacetate 

781666-30-6 

N4-[(4-fluorophenyl)methyl]-2-nitro-1,4-benzenediamine 150812-21-8 

ethyl {4-[(4-fluorobenzyl)amino]-2-nitrophenyl}carbamate 150812-23-0 

2,3-diaminobenzamide dihydrochloride 266993-72-0 

1-(tert-butoxycarbonyl)-2-methyl-D-proline 166170-15-6 

2-[(2S)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide dihydrochloride 912445-36-4 

2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide 912444-00-9 

1-(2-nitrobenzyl)-1H-pyrrole-2-carbaldehyde 22162-51-2 

5-fluoro-2-methylbenzoyl chloride 21900-39-0 

2-chloro-4-{[(5-fluoro-2-methylphenyl)carbonyl]amino}benzoic acid 168080-49-7 

ethyl 3-amino-4-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]but-2-enoate 265136-65-0 

N-(4-chloro-3-cyano-7-ethoxyquinolin-6-yl)acetamide 848133-76-6 

2-((2-chloro-4-nitrophenoxy)methyl)pyridine 179687-79-7 

(E)-4-(dimethylamino)but-2-enoic acid hydrochloride 848133-35-7 

2-cyano-N-(2,4-dichloro-5-methoxy phenyl)acetamide 846023-24-3 

2-(3-chloropropoxy)-1-methoxy-4-nitrobenzene 92878-95-0 

benzyl (3S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate hydrochloride 103733-32-0 

benzyl (2S,3aS,6aS)-octahydrocyclopenta[b]pyrrole-2-carboxylate hydrochloride 87269-87-2 

1,1'-binaphthalene-2,2'-diol --5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-

yl)methyl]sulfinyl}-1H-benzimidazole(1:1) 272776-12-2 

5,7-dioxa-6-thiaspiro[2.5]octane-6-oxide 89729-09-9 

(S)-3-(dimethylamino)-1-(thiophen-2-yl)propan-1-ol 132335-44-5 

(3S)-N,N-dimethyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine 132335-46-7 

A-27
methyl 2-((R)-3-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(((1-

(hydroxymethyl)cyclopropyl)methyl)sulfanyl)propyl)benzoate hydrochloride 00-00-0 

(2Z)-{[(1-tert-butoxy-2-methyl-1-oxopropan-2-yl)oxy]imino}[2-(tritylamino)-1,3-thiazol-4-

yl]ethanoic acid 68672-66-2 

1-(pyridin-4-yl)pyridinium chloride hydrochloride 5421-92-1 

2-(3-chloropropyl)-2-(4-fluorophenyl)-1,3-dioxolane 3308-94-9 

1-{1-[4-(4'-fluorophenyl)-4,4-ethylendioxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1,3-dihydrobenzimidazol-2-one 00-00-0 

2,5-bis(2,2,2-trifluoroethoxy)benzoic acid 35480-52-5 

1-phenyl-3-oxabicyclo[3.1.0]hexan-2-one 63106-93-4 

N2-[(benzyloxy)carbonyl]-L-glutaminyl-L-asparaginyl-S-benzyl-L-cysteinyl-L-prolyl-Lleucylglycinamide 21688-11-9 

(2R)-3-(benzylsulfanyl)-N-[(2S)-1-{[(2S,3S)-1-hydrazinyl-3-methyl-1-oxopentan-2-yl]amino}- 39570-96-2 

3-chloro-6-methyldibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide 26638-53-9 

3-alpha-hydroxy-7-oxo-5-beta-cholan-24-oic acid 4651-67-6 

diethyl ethyl(1-methylbutyl)malonate 76-72-2 

6-fluoro-3-oxo-3,4-dihydropyrazine-2-carbonitrile -- N-cyclohexylcyclohexanamine (1:1) 1137606-74-6 

ethyl 6-bromo-5-hydroxy-1-methyl-2-[(phenylsulfanyl)methyl]-1H-indole-3-carboxylate 131707-24-9 

(2S-3αS,7αS)-octahydro-1H-indole-2-carboxylic acid 80875-98-5 

N-[(2S)-1-ethoxy-1-oxopentan-2-yl]-L-alanine 82834-12-6 

3-{(E)-2-[(3R)-pyrrolidin-3-yl]ethenyl}-5-(tetrahydro-2H-pyran-4-yloxy)pyridine 753015-42-8 

4,6-dichloro-5-nitro-2-(propylsulfanyl)pyrimidine 145783-14-8 

(3aR,4S,6R,6aS)-2,2-dimethyl-6-(2-methylidene-4-phenylbutyl)tetrahydro-3aHcyclopenta[d][1,3]dioxol-4-ol 274693-53-7 

poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy, diester with 21N6, 21’N6-[[(N2, N6-dicarboxy-Llysyl-β-alanyl)imino]bis(1-oxo-2, 1-ethanediyl)]bis[N-acetylglycyl-L-leucyl-L-tyrosyl-L-alanyl-Lcysteinyl-L-histidyl-L-methionylglycyl-L-prolyl-L-isoleucyl-L-threonyl-3-(1-naphthalenyl)-L-alanylL-valyl-L-cysteinyl-L-glutaminyl-L-prolyl-L-leucyl-L-arginyl-N-methylglycyl-L-lysinamide] cyclic 

(6→15), (6’→15’) bis(disulfide) 

913976-27-9 

(1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-

amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-bis(methylene)-2,19,30,34,37,39,40,41-

octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-

one methanesulfonate 

441045-17-6 

4-chloro-3-methyl-1,2-oxazol-5-amine 166964-09-6 

5-(chloromethyl)-6-methyl-1,3-benzodioxole 117661-72-0 

methyl 3-(chlorosulfonyl)thiophene-2-carboxylate 59337-92-7 

(S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide 27262-47-1 

A-28
(3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride 1062580-52-2 

(3S,4aS,8aR)-2-(methoxycarbonyl)-6-oxodecahydroisoquinoline-3-carboxylic acid --(1R)-1-

phenylethanamine (1:1) 134388-95-7 

(3S,4aS,6S,8aR)-6-hydroxy-2-(methoxycarbonyl)decahydroisoquinoline-3-carboxylic acid 503293-98-9 

5-(2-chloro-6-fluorophenyl)-2H-tetrazole 503293-47-8 

(3S,4αS,6S,8αR)-6-[3-chloro-2-(2H-tetrazol-5-yl)phenoxy]decahydro-3-isoquinolinecarboxylic 

acid hydrochloride 503290-66-2 

2-ethylbutyl (3S,4αS,6S,8αR)-6-[3-chloro-2-(1H-tetrazol-5-yl)phenoxy]decahydro-3-

isoquinolinecarboxylate 4-methylbenzenesulfonate 503291-53-0 

5-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile 473921-12-9 

4-chloro-heptane-3,5-dione 13054-81-4 

5-hydroxybenzene-1,3-dicarbonitrile 79370-78-8 

methyl 2-((R)-3-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(((1-

(hydroxymethyl)cyclopropyl)methyl)sulfanyl)propyl)benzoate 936359-25-0 

A-29

APPENDIX B 

USITC’s Federal Register Notice of 

Institution

33824 Federal Register / Vol. 75, No. 114 / Tuesday, June 15, 2010 / Notices 

1The record is defined in sec. 207.2(f) of the 

Commission’s Rules of Practice and Procedure (19 

CFR 207.2(f)). 

Under the Alternative Technologies 

alternative, waste heat would involve 

the export of processed steam, instead of 

the steam being converted to electricity 

through the use of a steam turbine under 

the proposed alternative. Export of 

processed steam would necessitate a 

nearby steam host. There are no steam 

hosts currently available near the 

existing LECEF Phase 1 site; therefore, 

a steam host would have to be 

constructed, resulting in additional 

impacts outside of the existing 34-acre 

site. 

Under the proposed action 

alternative, we would issue an 

incidental take permit for the 

applicant’s proposed project, which 

includes the activities described above 

and in more detail in the HCP. The 

proposed action alternative is not 

expected to result in the permanent loss 

of habitat for any of the Covered 

Species. The proposed project is 

expected to result in indirect effects to 

10,306 acres of serpentine grassland. To 

mitigate these effects, the applicant 

proposes to permanently protect 40 

acres of serpentine grassland on Coyote 

Ridge, implement a monitoring and 

management plan for the Covered 

Species, establish a non-wasting 

endowment, and purchase Bay Area Air 

Quality Management District pollution 

credits. 

National Environmental Policy Act 

As described in our EAS, we have 

made the preliminary determination 

that approval of the proposed plan and 

issuance of the permit would qualify as 

a categorical exclusion under NEPA (42 

U.S.C. 4321 et seq.), as provided by 

Federal regulations (40 CFR 1500, 5(k), 

1507.3(b)(2), 1508.4) and the 

Department of the Interior Manual (516 

DM 2 and 516 DM 8). Our EAS found 

that the proposed plan qualifies as a 

‘‘low-effect’’ habitat conservation plan, 

as defined by our Habitat Conservation 

Planning Handbook (November 1996). 

Determination of low-effect habitat 

conservation plans is based on the 

following three criteria: (1) 

Implementation of the proposed plan 

would result in minor or negligible 

effects on federally listed, proposed, and 

candidate species and their habitats; (2) 

implementation of the proposed plan 

would result in minor or negligible 

effects on other environmental values or 

resources; and (3) impacts of the plan, 

considered together with the impacts of 

other past, present, and reasonably 

foreseeable similarly situated projects, 

would not result, over time, in 

cumulative effects to environmental 

values or resources that would be 

considered significant. Based upon the 

preliminary determinations in the EAS, 

we do not intend to prepare further 

NEPA documentation. We will consider 

public comments when making the final 

determination on whether to prepare an 

additional NEPA document on the 

proposed action. 

Public Review 

We provide this notice pursuant to 

section 10(c) of the Act and the NEPA 

public-involvement regulations (40 CFR 

1500.1(b), 1500.2(d), and 1506.6). We 

will evaluate the permit application, 

including the plan and comments we 

receive, to determine whether the 

application meets the requirements of 

section 10(a) of the Act. If the 

requirements are met, we will issue a 

permit to the applicant for the 

incidental take of the Bay checkerspot 

butterfly, coyote ceanothus, Metcalf 

Canyon jewel-flower, Santa Clara Valley 

dudleya, and Tiburon paintbrush from 

the implementation of the Covered 

Activities described in the plan, or from 

mitigation conducted as part of this 

plan. We will make the final permit 

decision no sooner than 30 days after 

the date of this notice. 

Dated: June 7, 2010. 

Susan K. Moore, 

Field Supervisor, Sacramento Fish and 

Wildlife Office, Sacramento, California. 

[FR Doc. 2010–14322 Filed 6–14–10; 8:45 am] 

BILLING CODE 4310–55–P 

INTERNATIONAL TRADE 

COMMISSION 

[Investigation No. 731–TA–149 (Third 

Review)] 

Barium Chloride From China 

Determination 

On the basis of the record1 developed 

in the subject five-year review, the 

United States International Trade 

Commission (Commission) determines, 

pursuant to section 751(c) of the Tariff 

Act of 1930 (19 U.S.C. 1675(c)), that 

revocation of the antidumping duty 

order on barium chloride from China 

would be likely to lead to continuation 

or recurrence of material injury to an 

industry in the United States within a 

reasonably foreseeable time. 

Background 

The Commission instituted this 

review effective July 1, 2009 (74 FR 

31757, July 2, 2009) and determined on 

October 5, 2009 that it would conduct 

a full review (74 FR 54069, October 21, 

2009). Notice of the scheduling of the 

Commission’s review and of a public 

hearing to be held in connection 

therewith was given by posting copies 

of the notice in the Office of the 

Secretary, U.S. International Trade 

Commission, Washington, DC, and by 

publishing the notice in the Federal 

Register on November 30, 2009 (74 FR 

62587). Counsel for the domestic 

interested party filed a request to appear 

at the hearing or, in the alternative, for 

consideration of cancellation of the 

hearing. Counsel indicated a willingness 

to submit written testimony and 

responses to any questions by a date to 

be specified by the Commission in lieu 

of an actual hearing. No other party filed 

a request to appear at the hearing. 

Consequently, the public hearing in 

connection with the review, scheduled 

for April 15, 2010, was cancelled (75 FR 

20625, April 20, 2010). 

The Commission transmitted its 

determination in this review to the 

Secretary of Commerce on June 9, 2010. 

The views of the Commission are 

contained in USITC Publication 4157 

(June 2010), entitled Barium Chloride 

from China: Investigation No. 731–TA– 

149 (Third Review). 

By order of the Commission. 

Issued: June 9, 2010. 

Marilyn R. Abbott, 

Secretary to the Commission. 

[FR Doc. 2010–14234 Filed 6–14–10; 8:45 am] 

BILLING CODE 7020–02–P 

INTERNATIONAL TRADE 

COMMISSION 

[Investigation No. 332–520] 

Pharmaceutical Products and 

Chemical Intermediates, Fourth 

Review: Advice Concerning the 

Addition of Certain Products to the 

Pharmaceutical Appendix to the HTS 

AGENCY: United States International 

Trade Commission. 

ACTION: Institution of investigation and 

invitation to file written submissions. 

SUMMARY: Following receipt of a request 

dated May 27, 2010 from the United 

States Trade Representative (USTR) 

pursuant to section 115 of the Uruguay 

Round Agreements Act (URAA) (19 

U.S.C. 3524) and section 332(g) of the 

Tariff Act of 1930 (19 U.S.C. 1332 (g)), 

the U.S. International Trade 

Commission (Commission) instituted 

investigation No. 332–520, 

Pharmaceutical Products and Chemical 

Intermediates, Fourth Review: Advice 

Concerning the Addition of Certain 

mstockstill on DSKH9S0YB1PROD with NOTICES


B-3
Federal Register / Vol. 75, No. 114 / Tuesday, June 15, 2010 / Notices 33825 

Products to the Pharmaceutical 

Appendix to the HTS. 

DATES: 

July 14, 2010: Deadline for filing all 

written submissions. 

September 1, 2010: Transmittal of 

Commission report to the United States 

Trade Representative. 

ADDRESSES: All Commission offices, 

including the Commission’s hearing 

rooms, are located in the United States 

International Trade Commission 

Building, 500 E Street SW., Washington, 

DC. All written submissions should be 

addressed to the Secretary, United 

States International Trade Commission, 

500 E Street, SW., Washington, DC 

20436. The public record for this 

investigation may be viewed on the 

Commission’s electronic docket (EDIS) 

at http://www.usitc.gov/secretary/ 

edis.htm. 

FOR FURTHER INFORMATION CONTACT: 

Information specific to this investigation 

may be obtained from Philip Stone, 

Project Leader, Office of Industries 

(202–205–3424 or 

philip.stone@usitc.gov). For information 

on the legal aspects of this investigation, 

contact William Gearhart of the 

Commission’s Office of the General 

Counsel (202–205–3091 or 

william.gearhart@usitc.gov). The media 

should contact Margaret O’Laughlin, 

Office of External Relations (202–205– 

1819 or margaret.olaughlin@usitc.gov). 

Hearing-impaired individuals may 

obtain information on this matter by 

contacting the Commission’s TDD 

terminal at 202–205–1810. General 

information concerning the Commission 

may also be obtained by accessing its 

Internet server (http://www.usitc.gov). 

Persons with mobility impairments who 

will need special assistance in gaining 

access to the Commission should 

contact the Office of the Secretary at 

202–205–2000. 

Background: As indicated in the 

USTR’s letter, as part of the Uruguay 

Round negotiations, the United States 

and 21 other countries agreed to 

eliminate duties on certain 

pharmaceutical products and chemical 

intermediates used primarily for the 

production of pharmaceuticals 

(pharmaceuticals zero-for-zero 

initiative) and to conduct periodic 

reviews to identify further products that 

could be covered by this duty 

elimination initiative. As a result of 

multilateral negotiations in the WTO in 

1996, 1998, and 2006, the United States 

and other participants eliminated duties 

on additional pharmaceutical items. The 

USTR indicated that participants in the 

zero-for-zero initiative are conducting a 

fourth review to determine if products 

can be added to the initiative. As part 

of the consultation and layover 

requirements in section 115 of the 

URAA relating to an action by the 

President to eliminate U.S. duties on 

additional pharmaceutical products and 

chemical intermediates, the President 

must obtain advice regarding the 

proposed action from the U.S. 

International Trade Commission. 

The USTR asked the Commission to 

provide advice in the form of 

information on the pharmaceutical 

products and chemical intermediates 

proposed for addition to the 

pharmaceuticals zero-for-zero initiative 

as follows: (1) A summary description of 

the products currently covered under 

the initiative as set out in the 

Pharmaceutical Appendix to the U.S. 

Harmonized Tariff Schedule (Appendix) 

and those proposed to be added to that 

Appendix; (2) an explanation of the 

relationship between the various 

elements in the Appendix and the 

Harmonized Tariff Schedule of the 

United States; and (3) an estimate of 

current U.S. imports and, where 

possible, current U.S. exports of the 

products included in the current 

Pharmaceutical Appendix and the 

proposed additions to the Appendix, 

based on product groupings as 

necessary. 

The Commission has posted a list of 

the proposed additions to the 

Pharmaceutical Appendix on its Web 

site at http://www.usitc.gov/ 

research_and_analysis/ongoing/ 

332_520_request_letter.pdf. The 

Commission expects to provide its 

report to the USTR by September 1, 

2010. 

Written Submissions: Interested 

parties are invited to file written 

submissions concerning this 

investigation. All written submissions 

should be addressed to the Secretary, 

and should be received not later than 

5:15 p.m., July 14, 2010. All written 

submissions must conform with the 

provisions of section 201.8 of the 

Commission’s Rules of Practice and 

Procedure (19 CFR 201.8). Section 201.8 

requires that a signed original (or a copy 

so designated) and fourteen (14) copies 

of each document be filed. In the event 

that confidential treatment of a 

document is requested, at least four (4) 

additional copies must be filed, in 

which the confidential information 

must be deleted (see the following 

paragraph for further information 

regarding confidential business 

information). The Commission’s rules 

authorize filing submissions with the 

Secretary by facsimile or electronic 

means only to the extent permitted by 

section 201.8 of the rules (see Handbook 

for Electronic Filing Procedures, http:// 

www.usitc.gov/secretary/ 

fed_reg_notices/rules/documents/ 

handbook_on_electronic_filing.pdf). 

Persons with questions regarding 

electronic filing should contact the 

Secretary (202–205–2000). 

Any submissions that contain 

confidential business information must 

also conform with the requirements of 

section 201.6 of the Commission’s Rules 

of Practice and Procedure (19 CFR 

201.6). Section 201.6 of the rules 

requires that the cover of the document 

and the individual pages be clearly 

marked as to whether they are the 

‘‘confidential’’ or ‘‘non-confidential’’ 

version, and that the confidential 

business information be clearly 

identified by means of brackets. All 

written submissions, except for 

confidential business information, will 

be made available for inspection by 

interested parties. 

In his request letter, the USTR stated 

that he intends to make the 

Commission’s report available to the 

public in its entirety, and asked that the 

Commission not include any 

confidential business information or 

national security classified information 

in the report that the Commission sends 

to the USTR. Any confidential business 

information received by the 

Commission in this investigation and 

used in preparing this report will not be 

published in a manner that would 

reveal the operations of the firm 

supplying the information. 

By order of the Commission. 

Issued: June 9, 2010. 

Marilyn R. Abbott, 

Secretary to the Commission. 

[FR Doc. 2010–14236 Filed 6–14–10; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Notice of Lodging of First Material 

Modification to a Consent Decree 

Pursuant to the Clean Air Act 

Notice is hereby given that on June 9, 

2010, a proposed First Material 

Modification to the Consent Decree 

entered in United States and the State 

of Kansas v. Coffeyville Resources 

Refining & Marketing, LLC et al., 04–cv– 

01064 (D. Kan. 2004), was lodged with 

the United States Court for the District 

of Kansas. 

The Consent Decree, entered by the 

Court on July 13, 2004 (Docket No. 8), 

required Defendants to install certain air 

pollution controls to reduce emissions 

of oxides, sulfur dioxide and particulate 

matter at their oil refinery located in 

mstockstill on DSKH9S0YB1PROD with NOTICES


B-4
APPENDIX C 

Written Submissions to the USITC

C-3
C-4
C-5
C-6
C-7
C-8
C-9
C-10
C-11
C-12
C-13
C-14
C-15
C-16
C-17
C-18
C-19
C-20
C-21
C-22
C-23
C-24
C-25
C-26
C-27
Additional intermediates to be included in the zero-for-zero update, in response to the US Trade Representative's invitation for comments, 75 Fed. Reg. 11,986 (March 12,2010) 

Submission Intercept Name 

# . I Description IName 

() 

N 

00 

10# Type 

589 CAS 

IUPAC 

2 590 CAS 

491 IUPAC 

3 591 CAS 

IUPAC 

4 592 CAS 

IUPAC 

5 593 CAS 

IUPAC 

6 594 CAS 

IUPAC 

HS-Code 

Carbamic acid, N-[(1 S)-1-methyl-2-oxo-2-[[(1 S)-2,3,4,5-tetrahydro-3-

2933.99 methyl-2-oxo-1 H-3-benzazepin-1-yl]amino]ethyl]- 1 1-dimethylethyl ester 

2-Thiabicyclo[3.1.0lhexane-4,6-di~arboxylic acid, 4-[((2S)-2-amino-4-

2934.99 Imethylthio)-1-oxobutyllaminol- 212-dioxide hydrate (1: 1), (1 R,4S,5S,6S)-

2-Thiabicyclo[3.1.0lhexane-4,6-ditarboxylic acid, 4-[((2S)-2-[((1, 1-

dimethylethoxy)carbonyllamin0]-4f(methylthio)-1-0xobl:llyllaminol-, 2,2-dioxide, sodium 

2934.99 salt (1:1), (1 R 4S 5S 6S)- : 

2-Thiabicyclo[3.1.0lhexane-4,6-di~arboxylic acid, 4-arrjino-, 2,2-

2934.99 dioxide (1 R 4S,5S,6S)-' ! 

! 

2-Thiabicyclo[3.1.0lhexane-4,6-di¢arboxylic acid, 4-amino-, 4,6-

2934.99 dimethyl ester 2 2-dioxide, (1 R,4S 5S 6S)- I . I 

Spiro[imidazolidine-4,4'-[2lthiabicyclo[3.1.0lhexanel-6'-carboxylic acid, 

2934.99 2 5-dioxo-{1'R,4S 5'S 6'S)-

Spiro[imidazolidine-4,4 '-[2]thiabicyclo[3.1 .Olhexane l-6'-carboxylic acid, 

CAS-RN Chemical Structure 

253324-93-5 

956385-05-0 

635318-07 -9 

635318-11-5 

635317-62-3 

635702-67 -9 

7r-__ ~5~95~C~A~S~ __ +-____ ~29~3~4~.9~9~2~5-~d~io~x~o-~2~'2~'-~d~io~xl~·d~e~(~1~'R~4~S~5~'~S,~6~'S~)·-__________________________________ r6~3~53~1~8~-~10~-4~ __ ~ 

! HO .• _0 :2,(::;, 

H I 

H HN)f"NH 

0:> 

IUPAC 

Benzoic acid, 4-[(2-[(5-bromo-4-(4-cyclopropyI1-1-naphthalenyl)-4H-1 ,2 ,4-triazol-3-

yllthio]acetyl]aminol-3-chloro- i 8~ __ ~59~6~C~A~S __ -4 ______ ~29~3~4~.9~9+-________________________________________________________ +8~7~8~6~70~-~61~-~2 __ ~ 

IUPAC 

Benzoic acid, 4-[[2-[[5-bromo-4-(4"cyclopropyl-1-nepht~alenyl)-4H-1 ,2,4-triazol-3- "-N 0 

yljthiojacelyljaminoj-3-chloro-, potassium salt (1:1) I or--<N),I.·s/';t".{_,\ 0 

9L-__ ..:::5:.::,9.:...7 ~C:::.A.:::S::"-__ .l.-____ --!:.29:::.:3~4:.:.:,9~9~ _______________________________ -+I _______________________ -L.::8:..:.7~86:::..7:....:0::...-6:::.:3~-4';':""' __ -J ("'('1) c/--""-'C 
. 

IUPAC . : 

Acetic, acid, 2-[[5-bromo-4(4-cyclbpropyl-1-naphthalenyl)-4H-1 ,2 ,4-triazol-3-yljthioj10r-__ ~59~8~C~A~S __ ~ ______ ~29~3~4~.9~9+-________________________________ ~ ______________________ +8~7~8~67~2~-~OO~-~5 __ ~ 

IUPAC 

Acetic acid, 2-[[5-bromo-4-( 4-cyclopropyl-1-riaphthale~yl)-4H-1 ,2 ,4-triazol-3-yljthio]- Sodium 

11r-__ ~59~9~C~A~S __ ~ ______ ~29~3~4~,9~9+S~a~lt~(~1:~1~) ______________ ~ ___________ r-I' ___ ' __________________ -+1~1~5~15~1~6~-1~4~-1~~ 

I 

IUPAC i 

12r-__ ~6~OO~C~A~S~ __ +-____ ~29~3~3~.9~9+3~H~-~1~2~4~-~Tr~ia~z~o~le~-3~-t~h~io~n~e~5~-~am~ih~o-~4~-(~'4-~c~y(c~lo~)p~lrO~)p~YII-41i-~n~ap~lh~th~a~le~n~Y'~II)I.-~2~4~-d~i~hy~(d~ro~-________ r8~7~86~7~1~-9~6~-6~ __ ~ ,4 1 

IUPAC 

13~ __ ~6~O~1rC~A~S~ __ +-____ ~2~92~1~.4~9~1-~N~a~Plht~h~al~e~na~m~i~n~e~4~-c~~~lc~lo~Plro~pv'II_-____________________________________ ~8~7~8~67~1~-~94~-4~ __ -4 

IUPAC 

14~ __ ~6~O~2rC~A~S~ __ +-____ ~29~3~3~.9~9~1H~-~ln~d~o~le~-3~-~a=ce~ta~m~id~e~1~-~m~e~th~YII~1 ____________ ~ ________________________ ~1~5~O~1~14~-4~1~-~3 __ ~ 

IUPAC i 

15r-__ ~6~O~3rC~A~S~ __ +-____ ~29~3~3~.3~9~1H~-~ln~d~o~le~-3~-~a=ce~tl~'c~a~ci~d~,a~-~ox~o~-~1-~[:11~-(~:2~-p~yrrid~i~ny~llm~et~h~yll~).-~4-~piip~le~rid~i~ny~lllw·-~m~e~th~lY~11~es~t~er~ ______ ~6~1~6~89~8~-6~4~-~7 __ --4 

IUPAC 

16r-__ ~6~O~4rC~A~S~ __ +-____ ~29~3~3~.3~9~1H~-~ln~d~o~le~1~-[~1-~(:2~-~pyrn~'d~in~yll~m~e~th~YII)-4~-p~iip~le~ri~d~in~YII]~.-__ ~ ________________________ ~5~9~4~82~7~-~31~-~3 __ --4 

IUPAC 

<J'I<' 

r:';;:~"/O'.,,,-:'---\ 

I r \'. i' ~~ ~l >-~,"~~,1 -,.- ),r-NH 

<) 

IUPAC 

26 614 CAS 2907.19 1[1 1'-Biphenyl]-4-ol, 4'c(1 1-dimethylethyl)-2 6-dimethyH 906101-33-5 \ 

V-I:n>-7~>-OH / .=- )=. 

IUPAC 

Propanamide, N-[(5S)-4-(2,2-dimethyl-1-oxopropyl)-5-[[[[2-

oP-.X (ethyla mine )ethyl]sulfonyl]amino jmethyl]-4 ,5-dihydro-5-phe nyl-1 ,3 ,4-thiad iazol-2-yl]-2 ,2-

615 CAS 2935.00 dimethvl- 910634-41-2 

N-[4-(2,2-DimethylpropionyIH5S)-5-[(2-ethylaminoeth~nesulfonylamino)methyl]-5-phenyl-4,5- +"''-' 

27 

IUPAC dihydro-[1,3,4 ]thiadiazol-2-yl]-2 ,2-dimethylpropionamid'e 

Carbamic acid, N-[[(2R)-3-(2,2-dimethyl-1-oxopropyl)-5-[(2,2-dimethyl-1-oxopropyl)amino]-2,3 

28 616 CAS 

IUPAC 

2934.99 dihvdro-2-phenvl-1 

Carbamic 

dihydro-2-phenyl-1 

Propanamide, 

acid, 

N-[(5R)-5-( 

[[(2R)-3-(2,2-dimethyl-1-oxopropyl)-5-[(2,2-dimethyl-1-oxopropyl)aminol-2 

,3,4-thiadiazol-.2-yllmethyll-, 

34-thiadiazol-2-vllmethvllaminomethyl)-4-(2 ,2 -d 1 

1,1-dimethylethyl 

imethyl-1-oxopropyl)-4 

1-dimethvlethvl ester 

ester 

,5-dihydro-5-phenyl-

,3-

910634-47-8 

~ 

ofi:t- 617 CAS 2934.99 1 3 4-thiadiazol-2-yl]-2 2-dimethyh, monohydrochloride 910788-86-2 

Propanamide, N-[(5R)-S-(amino~ethyl)-4-(2 ,2 -dimethyl-1-oxopropyl)-4 ,S-d ihydro-S-phenylIUPAC 1,3,4-thiadiazol-2-yl]-2,2-dimethyH, hydrochloride (1 :1): 

29 

618 CAS 2906.29 Benzoic acid 4-[( 1 R)-4 4 ,4-trifluoro-1-hvdroxvbutvll-, methvl ester 953422-94-1 

H~!-Q- I C02Me 

( -

30 

> F:)C 

IUPAC (R)-4-(4,4,4-Trifluoro-1-hydroxybutyl)benzoic acid methyl ester 

619 CAS 2934,99 1-Piperazinepropanoic acid 4-dibenz[b,f][1 4]oxazepih-11-yl-a,a-dimethyl- methyl ester 1057253-63-0 

-7) _\~; . 

31 .. I 

N, 

:~N .> 

.0-

,>,. "1.~ 

IUPAC '." r.:l 

32 620 CAS 2933.S9 1-Piperazinepropanoic acid a a-dimethvl- methvl ester,hvdrochloride (1 :2) 1198178-S6-1 

~" 

CN -> 

"O)~) .~ He' 

IUPAC 

Propanamide, N-[(SR)-4-(2,2-Dimethyl-1-oxopropyl)-5-f[[2-

33 621 CAS 293S.00 

(ethylamino 

dimethvl- (2Z)-2-butenedioate 

)ethyl]sulfony]amino 

(1:~) 

]rriethyll-4 ,S-dihydro-S-phenyl-1,3 ,4-thiadiazol-2-yl]-2 ,2-

1198179-08-6 (f_r'L~., ~y 
() 

W 

N 

34 

35 

36 

37 

38 

39 

40 

4 1 

622 

623 

624 

625 

626 

627 

628 

629 

IUPAC 

CAS 

IUPAC 

CAS 

IUPAC 

CAS 

IUPAC 

CAS 

IUPAC 

CAS 

IUPAC 

CAS 

IUPAC 

CAS 

IUPAC 

CAS 

N-[4-(2,2-DimethylpropionyIH5S)~5-[(2-ethylaminoethanesulfonylamino)methyl)-5-phenyl-4,5-

dihydro-[1,3,4)thiadiazol-2-ylj-2,2-~imethylpropionamide fumarate 

2934.99 9H-Carbazole 4-[(2Sl-2-oxiranYlmethoxvl- 95093-95-1 

, 

I 

3-Pyridinecarboxamide, 6-[4-[2-[d-(9H-Carbazol-4-yIOxy)-2-hYdroxyprOPYljamino]-2-

methylpropyl]phenoxy]-, (S)-; 

2933.39 3-pyridinecarbonitrile 6-f4-(2-amino-2-methylpropyl)phenoxvJ- 189119-39-9 

Butanedioic acid, compd. with 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl)amino)-

2933.39 2-methylpropyl]phenoxy)-3-pyridinecarboxamide (1 :2) 204593-36-2 

2-Propanesulfonamide, N-[(2R)-2-[4'-[2-[(methylsulfonyl)amino ]ethyl](1,1'-biphenyl]-4-

2935.00 yl)propylJ- 375345-95-2 

2934,99 2H-Pyran-4-propanamide a-(4-(cyclopropylsulfonyl)phenyIJtetrahydro-N-2-pyrazinyl- (aR)- 745051-65-4 

I 

" 2932.99 Benzeneacetic acid 4-(cyclopropylsulfonyl)-a-[(letrah-Alro-2H-pyran-4-yl)methyleneJ- (aE)- 745052-98-6 

I , 

I 

2932.99 2H-Pyran-4-propanoic acid a-[4-(cyclopropylsulfonyl)Rhenyljtetrahydra- (aR)- 745053-49-0 

I 

I 

!3-Alanine, N-[4-[1-[[4'-(1,1-dimethylethyl)-2,6-dimethyID1,1'-biphenyl]-4-yljoxy)-4,4,4-

2924.29 trifluorobutyljbenzoylj-, (-)-.. .. 872260-20-3 

...,. J"-.?-N .. "r~"" .J.". 01 "oyl 

, 

(lJO:::'JJ 

.C·' 

~ 

-'r'"""] .. K!l.z II _~ '.~ II I No.-C-CS, 01', I 

... 

eto 

I 

. ,,...,..,,,',".,, )"~ OY"'" ~.--'"-,, .. 

.,."(",,,/ 

(.. fk ~~.~I/'_·'· 

.-'~, 

I I 

-' r.~::,: 

,/\, f.) 

'"" 't _ .... /.'[ 

,.~\:J(::/'& 011 

v 0 

.. -~ 

0 

l ...... ~ 

/''-' .. )~(OH q,.l/;. b s '.' r:::-!"' ,I y' 0 

",--:::.,yi .••. ,.",/:t!,1 
I J ; . ';, # ~ 

II J I 

((I' l. ,3, 

. ~ .. ,.., ~ 

IUPAC 

630 CAS 2934.99 N-[S-bromo-4-methyl-2-[{2S1-2-mbrpholinylmethoxvlphenvll-N'-{5-methvl-2-pyrazinyll-urea 911222-45-2 

I· -."~~ 

0 0(' I, f) 

H >1 t 

,.,.'(:.: N)" 0iC,:~, ... 

42 

6, 

IUPAC " 

631 CAS 2933.99 5-Fluoro-2-oxindole : 56341-41-4 'Dr ; 

~ N i H 

43 

IUPAC I I 

632 CAS 2933.79 1 H-Pyrrole-3-carboxvlic acid, 5-form~I-2,4-dimethYI- J 253870-02-9 (J:- I 

IUPAC 

44 

633 CAS 2932.99 Magnesium, chloro[(6-methyl-1, 3-bertzodioxol-5-yl)methyl]- I 1008726-80-4 

I I C"Mo~) ~ 0 

45 

IUPAC 

1 H-Pyrido[ 4, 3-b)indole, -2,3,4, 5-tetrahydro-2, 8-dimethyl-5-[2-(6-methyl-3-pyridinyl)ethyl)-, hydrochloride, '0))/ 634 CAS 2933.39 hydrate (1 :2:2) I 1186653-04-2 

I 9 '"'" '..,0 

46 

IUPAC Dimebon dihydrochloride dihydrate 

635 CAS 2932.99 6,1 O-Dioxaspiror 4. 51decane-7 -acetic acid, 9-( cyanomethyl)-,1, 1-dimethylethyl ester, (7R, 9R)- 1035204-82-0 Q F·X: 

47 

IUPAC 

1 H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1 ,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-N- 0 636 CAS 2933.99 2-( 1-pyrrolidinyl)ethylj- I 356068-94-5 

.vJ}:~ . , . ~ 

48 

IUPAC ; 

1 H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxq-3H-indol-3-ylidene)methyl)-2,4-dimethyl-N- 0 637 CAS 2933.99 2-(1-pyrrolidinyllethyl)-, phosphate (1: 1 l 874819-74-6 0 r-./ 49 

N" 

. ~ 

~ 0 ",PO, 
o 

F 

~r ~ ...... *'0. 

IUPAC ~ Toceranib phosphate 

638 CAS 2921.42 Benzenamine, 4-(phenylmethoxy)-, hydrochloride (1 :1) I 51388-20-6 I 

~N-O° ~ 

50 

IUPAC ~ 

639 CAS 2914.70 1-Propanone, 2-bromo-1-[4-(phenylmethoxy)phenylj 35081-45-9 

~~ i 

51 

IUPAC Ii! 

52 640 CAS 2933.99 1 H-Indole, 3-methyl-5-(phenylmethoxy)-2-[4-(phenylmethoxy)phenyll- 198479-63-9 

o-~rD IUPAC • 

53 641 CAS 2933.99 Benzenemethanol, 4-[2-(hexahydro-1'H-azepin-1-yl)ethoxvj-, i hydrochloride (1: 1) 328933-65-9 "" ! 

011 

ro 

IUPAC 

642 CAS 2931.00 1,3 2-Dioxaborinane-5-carboxylic aciC/ 5-methyl-2-phenyl- 839720-60-4 

~K)-o 

54 

IUPAC 

2-Naphthacenecarboxamide, 9-ami~t~, 7 -bis(dimethylamin9)-1 ,4,4a,5,5a,6,11,12a-octahydro643 CAS 2924.29 3,1 O,12,12a-tetrahydroxy-1,11-dioxo-, onohydrochloride, (4S-(4a,4aa,5aa,12aa» 149934-21-4 

~ 

f I' ~ " 

N~ L 

55 

IUPAC ~ G 011 13 13 

I 

644 CAS 2922.50 2"(tert-butylamino)acetic acid hydrocHloride 6939-23-7 0 

: 

XU'H I 

.- , 

IUPAC I 

56 

57 645 CAS 2922.50 2-(tert-butylamino)acetyl chloride hydrochloride 915725-52-9 0 
X~~CI IUPAC 

o 

646 CAS 2922.50 Cyclohexanol, 1-[2-amino-1-(4-methoxyphenyl)ethyi]-, acetate (1: 1) 839705-03-2 .CHlCOOH 

MoO J+ ""'" 

58 

IUPAC 

648 CAS 2933.19.90.90 3H-Pyrazol-3-one, 1 ,2-dihydro-5-met~yl-1-(2-naphthalenyl)- . 1192140-15-0 0 OH 

H3CJ)H H,Cf) 

~ C6 

IUPAC 5-methyl-1-(naphthalen-2-yl)-1 H-pyra;zol-3-ol 

59 

649 CAS 2934.99.90.90 Morpholine, 4-(2-chloroethyl)- , 3240-94-6 

CI~r-"-o 

IUPAC 1-Chloro-2-morpholinoethane , NV 

60 

651 CAS 2934.99.90.90 1 ,2-Benzisoxazole, 6-fluoro-3-(4-pipe~idinyl)-, hydrochloride (1: 1) 84163-13-3 

! 

HN 

~ I Hel F 

61 

IUPAC I 6-fluoro-3-(piperidin-4-yl)benzo[dliso$zole hydrochloride 

653 CAS 2933.39 Pyridine, 5-ethenvl-2-methvl-, ethane~ioate, hvdrate~2:3:~ 1202745-66-1 f) 0 0 

N ·1.5U 

OH OH 

62 

HfJ 

IUPAC 

654 CAS 2933.39 2-Pyridinamine, 3-[(1 R)-1-(2, 6-dichlorb-3-fluorophenyl)ethoxyj-5-[ 1-( 4-piperidinvll-1 H-Dvrazol-4-vll- 877399-52-5 DH N-N 

63 

¢Co CI ~ N 

~ I CI N~ 

IUPAC F 

64 655 CAS 2906.29 Benzenemethanol, 2,6-dichloro-3-fluoro-a-methyl-, (as)- 877397-65-4 CI ¢CoH 

~ CI 

F 

IUPAC , 

65 656 CAS 2935.00 Acetic acid, 2-[ 3-[[[[ 4-( 1 , 1-dimethylethyl)phenyljmethyl]( 3-pyridinylsulfonyl)amino lmethvllohenoxvl- 223488-57-1 ... 
() 

w 

C]) 

66 

67 

68 

69 

70 

71 

72 

43 

IUPAC 

657 CAS 

IUPAC 

658 CAS 

IUPAC 

659 CAS 

IUPAC 

660 CAS 

IUPAC 

661 CAS 

IUPAC 

662 CAS 

IUPAC 

663 CAS 

IUPAC 

664 CAS 

Acetic acid, 2-[3-[[([4-(1, 1-dimethylethyl)phenyllmethylj(3-pyridinylsulfonyl)aminolmethyllphenoxyl-, 

2935.00 sodium salt (1:1) 223490-49-1 

2-Butenamide, N-[4-[ (3-chloro-4-fluorophenyl)aminol-7 -melhoxy-6-quinazolinylj-4-( 1 -piperidinyl)-, 

2933.59 hydrate (1: 1), (2E)- 1042385-75-0 

Acetic acid, 2-[3-[[[[4-(1 H-pyrazol-1-yl)phenyljmethylj(3-pyridinylsulfonyl)aminolmethyllphenoxyj-, 1-

2935.00 methylelhyl ester 1005549-94-9 

Azepino[4,5-blindole-5-carboxylic acid, 3-(3,4-difluorobenzoyl)-1 ,2,3,6-telrahydro-1, 1-dimethyl-, 1-

2933.99 methylethyl ester 629664-81-9 

2933.99 l-Proline, glycyl-4-(benzoylamino)-, (4R)- 943134-39-2 

2922.19 3 Amino 1,2 Propane Diol 616-30-8 

. i 

2933.99 1 H~lndole-1-acetic acid 4~(acetylamino)-3-r(4-chlorODhenyl)thiol-2-me 802904-66-1 , 

4-(Acetylamino )-3-[ (4-chlorophen~l)thio J-2-methyl-I H -indole-I-acetic acid 

N-( 4-« 6, 7 -dimethoxy-4-quinolinyl)oxy)p~enyl)-N'-( 4·11 uoropheny,1 )-I,I-cycl opropanedicarboxamide, L-malic 

2933.49 acid salt (1:1) 1140909-48-3 

'. pfJ 

"~ , .... 

p'~ 

o U H'--O:' 7rU:)H.Oe

, o J H 

JYl;:D'°J/, 

G 0'0 N 

.'6y2tc 

'("" o D/Co,H cr~ 

*t I,H 0 I ~ 

Jq"J"l'fi,-=. tq). " J .... rn 

.~, ( - .. ...... 

_W:~ 

HO,C-CR, 

I c. I('J"'I('''' .J(.~,,( ·~f s ~,::" 

''''''' 

(y' ~« ~ , 

I -, 
)J ; ; v. ~yY" . " 

''X}) Of' 

N-[4-[(6, 7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl )-1, I-cyclopropanedicarboxamide, compd. " I 

IUPAC with (2S)-2-hydroxybutanedioic acid (I: ID 

74 665 CAS 2933.49 N-( 4-((6 7-dimethoxy-4-Quinol inyl )oxy)phenyl l-N'-( 4-fluorophenyl)- 1 I-cyclopropanedicarboxamide 849217-68-1 

v ~1t: ,0 GO U, 

"m ' o • ' 

IUPAC . 

666 CAS 2924.29 1-(l4-fluorophenyl)carbamoyl)cycIOjJropanecarboxvlic acid 8492 17 -48-7 

HO~~D- a 0 1 F 

75 

IUPAC 

667 CAS 2933.49 4-«6,7 -dimethoxy-4-quinolinyl)oxy)aniline I 190728-25-7 I 00 ... · 76 

I /om 

IUPAC I I ..... 0 I Hi!) 

methyl «1 S)-1-«(2S)-2-(4-(4 '-(2-«?S)-1-«2S)-2-«meth'oxycarbonyl)amino)-3-methylbutanoyl)-

~li ,){}{}{A 1- 2-pyrrolidinyl)-1 H-imidazol-4-yl)-4-biphenylyl)-1 H-imid~zol-2-yl)-1-pyrrolidinyl)carbonyl)-2-

668 CAS 2933.29 methylpropyl)carbamate, dihydrochloride i 1009119-65-6 iif: '."i{ 

IUPAC '- i 

77 

669 CAS 2914.70 1,1 '-I 4,4'-biphenyldiyl)bis(2-bromoethanone) I 4072-67-7 t-o--c>1 I 

8r at 

78 

IUPAC 

670 CAS 2933.99 I-(tert-butoxycarbonyl )-L-prol i ne 15761-39-4 

I?,. 

0.:.:(0 .. \:' 

N 

79 

; ......... . , ><0 \H"'! 

IUPAC 

671 CAS 2924.19 N-(methoxycarbonyll-L-valine 74761-42-5 (J 

MeO "I( ~.(Jl··OH 

80 

IUPAC 0 .. /:....,~., 

tert-butyl (2S)-2-( 4-( 4'-(2-((2S)-I-(tert-butoxycarbonyl)-2-pyrrol idinyl)-I H-imidazol-5-yl)-4-biphenylyl)-1 H- oJ( 672 CAS 2933.29 im idazol-2-yl )-I-pyrrol idinecarboxylate 1007882-23-6 0;0 "t)--O--CX «:: 

81 

IUPAC 

y 

673 CAS 2933.29 4,4'-(4,4'-biphenyldiyl)bis(2-«2S)-z-pyrrolidinyl)-1 H-imidazole), hydrochloride (1:4) 10091 19-83-8 .~ P 

I ~J}-O-O{N IUPAC 

U" 

82 
(') 

w 

00 

83 

84 

85 

86 

87 

88 

89 

91 

92 

93 

674 

675 

677 

678 

679 

680 

681 

682 

683 

684 

CAS 2935.00 

IUPAC 

CAS 2935.00 

IUPAC 

CAS 2935.00 

IUPAC 

CAS 2935.00 

IUPAC 

CAS 2933.59 

IUPAC 

CAS 2933.59 

IUPAC 

CAS 2935.00 

IUPAC 

CAS 2935.00 

IUPAC 

CAS 2935.00 

IUPAC 

CAS 2935.00 

(2R)-2-([ (4-chlorophenyl )sul fonyll [[2-11 uoro-4-( 1.2. 4-oxad iazol-3: yl )phenyl J methyl lam i no l-5.5.5-

tritluoropentanamide 

R)-2-[[( 4-Chlorophenyl)sul fonyllamino ]'5,5 5-trifluoropentanamide 

, 

I (2R )-2-[[( 4-chlorophenyl )sulfonyllf( 4-cyano-2-f1 uorophenyl )methVl]amino ]-5 5,5-trifluoropentanamide , 

i 

(2 R )-2-[[( 4-chlorophenyl )sul fonyl ][[2-tl uoro-4-[ (hydroxyam i no)i rjtinomethy1lpheny1lmethyl]ami no l-5,5,5-

tritluoropentanamide i 

Benzoic acid 4-[4-([2-( 4-chlorophenyl)-S 5-dimethyl- 1 -cyclohexen-I-yllmethyl]-I-piperazinyll-, ethyl ester 

I 

! 

ethyl 4-(4-{ (2-( 4-chldroPhenYll-5,5-dimelhYlcycloheX-I-en-I-YllnlethYI) piperazin-I-yl)benzoate 

; 

Benzoic acid, 4-[4:112-(4-chiorophenYI)-5, 5.dim!tthyl.' -cyclohexen·', /t]methyt]-1-piperazinyt]· 

4.( 4-{[2-( 4-chlorophenyl)-5,5-dimethylcyclohex,1-en-1-yljmethyl)piperazin-' ·yl)benzoic acid 

Benzenesuffonamide, 4-fluoro.3.[(trifluorometh~l)suffonYIIi 

, 

4.fluoro.3.[(lrifluoromelhyl)sUlfonyljbenzenesulionamide 

Benzenesulfonamide, 4-[[(1 Rl-3-(4.morpholinyl)-1-[(phenyllhid)methyIJpropyIJamin0)-3-

![(trifluoromelhyl)Sulfonyl]-, hydrochloride (1: 1) ! 

i 

4-{[(2R )-4.(morpholin-4-yl)-1-(phenylsu~anyl)b~lan-2-yllamino)-3·[(Irifluoromelhyl)su~onyljbenzenesulfonamide hydrochloride 

Benzamide, 4-[4-[[2-(4-chlorophenyl).5,5-dimethyl-1-cyclohexen-1-yllmelhyIJ-1.piperazinylj-N-{[4.[[( 1 R).3-{4-morpholinyl).'. 

[(phenylthio)methyljpropyljaminoj.3-[(lrifluoromethyl)Su~onyllphenyllsulfonylj-, hydrochloride (' :2) 

i 

4-(4.([2 -( 4-chlorophenyl)-5,5-dimelhylcyclohex.' -en-' .yl)methyl)piperazin".yl)·N .[( 4-{[(2R )-4-(morpholin-4-yl).'. 

(phenylsuffanyl)butan-2-yllamino}-3-(lrlfluoromelhyl)suffonyljphenyl)suffonyljbenzamide dihydrochloride 

Benzamide, 4·[4-[(2-( 4-chlorophenyl)·5,5·dimelhyl·1-cyclohexen· , -yllmethyll·'·piperazinylj-N-[(4.[( 1 R)·3-( 4·morpholinyl).'. 

(phenyllhio)methyl)propyl)aminoj·3·{(lrifluoromelhyl)su~onyljphenylJsulfonylJ-

~ 1146699-66-2 co 

'!o I H,. _ ... ~ 

o~ • I .~ ·'0 

1146699-67-3 

CP, 

H'N~ 0 

"-0- o HN-~ ~ h CI 0 

NH, 

1146699-69-5 ~VCF' 

CI-o-~-N~ - g 9' ~ eN 

F 

H,H I) ~Q 

1 146699-70-8 ~~XH:\ 

~ .. ",-' 

1065604-70-7 QI'~ 

C:::J 

"~ 

, 044598-91-5 ¢,. 

C:;::J 

"~ 

1027345-08-9 CF1Y 

H,N)i 

ob 

1213227-71-4 

~ 109385' -28-5 

~6D c?'He, tv 923564·5'·6 'x' .. ~ ..c:r -:-.'1, ~\ (" .. ,. 
() 

w 

co 

90 

99 

95 

96 

97 

98 

102 

103 

104 

106 

685 

686 

686 

690 

691 

692 

693 

694 

695 

696 

650 

IUPAC 

CAS 

IUPAC 

CAS 

IUPAC 

CAS 

IUPAC 

CAS 

IUPAC 

CAS 

IUPAC 

CAS 

IUPAC 

CAS 

IUPAC 

CAS 

IUPAC 

CAS 

IUPAC 

CAS 

4.(4-([2-( 4-Chlorophenyl)-5.5-dimelhylcyclohex-l-en-l-yllmethyl}piperazin-~ -yl)-N -( (4-( « 1 R )-3-morpholin-4-y!-1-

[(phenylsuffanyl)methyllpropyl}amino)-3-[(trifluQromethyl)sulfonyllphenyl}sul onyl)benzamide 

2934.99 4-Morpholinepropanamine, a-[(phenylti1lio)methylj-, (aR)-, (2R,3R)-2,3-dihydroxvbutanedioate (1: 1) 1211996-70-1 

(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-amine 2,3rdihydroxybutanedioate (salt) 

Acetic acid. 2-{2-oxocyclopent~lidene)-{E) with N-~1-methylethyl)-2-propanamine 

1{1: 1). ) 1206547-75-2 : 

3,5-Pyridinedicarboxylic acid, 4-(2-chlorophenyl)-2-[[2-( 1, 3-d!hydro-1.3-dioxo-2H-isoindol-2-

2933.39 yl)ethOxy)methyl)-1,4-dihydro-6-meth~I-, 3-ethJ'1 5-methyl ester 88150-62-3 

I 

, 

2933.59.70 

Propanoic acid, 2,2-dlmethyl-, [4-[1-[(1 R)i2-cyano-l-cyclopentylethylj-l H-pyrazol-4-ylJ-7H-pyrrolo[2,3-djpyrimidin-7· 

yljmethyl ester i 1146629-80-2 

: 

2933.59.70 Propanoic acid, 2,2-dimelhyl-, [4-(1 Hpyrakol-4-yl)-7H-pyrroIO[2,3-djpyrimidin-7-yljmethyl ester 1146629-77-7 

I 

t . 

, 

2926.90.50 2-Propynenitrile, 3-cyclopentyl- 941685-68-3 . 

2933.59.70 (Z) -( 4-(1-(2-cvano-1-cvclooentvlvinvlJ-1 H-oyrazo/-4-vl)-7H-ovrro/o{2, 3-dlovrimidin-7 -vllmethvl Divalate 

2933.59.70 : (Z)-( 4-( 1-(3-amino-1-cvclooentYI-3-o¥ ooroo-1-enyl)-1 H-oyrazo/-4~y/)-7H-ovrro/or2. 3-dIDvrimindin-7 -vllmethvl Divalate 

2933.59.70 (RJ-( 4-(1-amino-1-cyclooentyl-3-oxooropyl}-1 H-pyrazDI-4-y/J-7H-pyrro/o[2. 3-dlDvrimidin- 7 -vnmethvl oivalate 

: 

2932.19.00.90 1,3-Dioxolane-2-acetic acid, 2,4-dimejhyl-, ethyl ester 6290-17-1 

(1 C··--'· 1 - _J .. :Ff" "0 

C? 

"r..-O -.,>-<. C.::J :.; .:. 

i 

~.~ .. ~ 

~-

6~-,>< 

~ ~CN 

S--._ 

~-~ 

~---

~~---"::--=:.. 

!ft;z~ 

h 
() 

.J".. 

o 

107 

108 

100 

101 

94 

652 

676 

687 

687 

688 

689 

IUPAC 

CAS 2933.39.99.90 

IUPAC 

CAS 2926.90 

IUPAC 

CAS 

IUPAC 

CAS 

IUPAC 

CAS 2916.39 

IUPAC INN 

2,4-0imethyl-2-[(ethoxycarbonyl)methyl]-1,3-dioxolane 

2-Pyridinamine, 3-(phenylmethoxy)- 24016-03-3 a::: :;::=:;t: ---- ~-

3-(benzyloxy)pyridin-2-amine ~' 

4-(bromomethyl)-3-f1uorobenzonitrile 105942-09-4 -'9--

748810-28-8 

(3 R )-1-[ ( 1 R, 2 R )-2 -[2 -( 3 ,4-dimethoxyphenyl )ethoxy jcyclohexyllPyrrolid m-3-ol 

hydrochloride 

3R, 6S )-3-am ino-6-(2, 3-difluorophenyl)hexa hydro-1-(2, 2, 2-trifluoroethyl )-2H-azepin-2-

one hydrochloride, compd, with 2-methoxy-2-methylpropane (1: 1: 1) 

Benzeneacetic acid, a-methyl-4-(2-methylpropyl)- 15687-27-1 

Ibuprofen "·-.1~-
C-41
C-42
C-43
C-44
C-45
C-46
C-47
C-48
C-49
C-50
C-51
C-52
C-53
C-54
C-55
C-56
C-57
C-58
C-59
C-60
C-61
C-62
C-63
C-64
C-65
C-66
C-67
C-68
C-69
C-70
C-71
UNITED STATES - IMPORT 

Period 

Harmonized Code 

Date Harmonized Code 

Dec-08 29242962 10 

Dec-08 2924296210 

Dec-08 2924296210 

Dec-08 2924296210 

Dec-08 29242962 10 

Dec-08 2924296210 

Dec-08 2924296210 

Dec-08 2924296210 

Dec-08 2924296210 

Dec-08 2924296210 

Dec-08 2924296210 

Dec-08 2924296210 

Dec-08 2924296210 

Dec-08 2924296210 

Dec-08 2924296210 

Nov-08 2924296210 

Nov-08 2924296210 

Nov-08 2924296210 

Nov-08 2924296210 

Nov-08 2924296210 

Nov-08 2924296210 

Nov-08 2924296210 

Nov-08 2924296210 

Nov-08 2924296210 

Nov-08 2924296210 

Nov-08 2924296210 

Oct-08 2924296210 

Oct-08 2924296210 

Oct-08 2924296210 

Oct-08 2924296210 

Oct-08 2924296210 

Oct-08 2924296210 

Oct-08 2924296210 

Oct-08 2924296210 

Sep-08 2924296210 

Sep-08 2924296210 

01/2008 to 12/2008 

2924296210 - ACETAMINOPHEN 

Country of 

Purchase District of Entry 

FRANCE CHICAGO, ILLINOIS 

FRANCE PHILADELPHIA, PA. 

TURKEY LOS ANGELES, CALIFORNIA 

IN DIA NEW ORLEANS, LOUISIANA 

CHINA DETROIT, MICHIGAN 

TURKEY LOS ANGELES, CALIFORNIA 

FRANCE M OBILE, ALABAMA 

CHINA LOS ANGELES, CALIFORNIA 

ITALY CLEVELAND, OHIO 

CHINA NEW YORK CITY, NEW YORK 

TURKEY LOS ANGELES, CALIFORNIA 

CHINA PHILADELPHIA, PA. 

FRANCE CHARLESTON, S. CAROLINA 

CHINA CHICAGO, ILLINOIS 

TURKEY LOS ANGELE5, CALIFORNIA 

CHINA WI LMINGTON, N. CAROLINA 

CHINA CHARLESTON, S. CAROLINA 

TU RKEY LOS ANGELES, CALIFORNIA 

IN DIA NEW ORLEANS, LOUISIANA 

CANADA NEW YORK CITY, NEW YORK 

TU RKEY LOS ANGELES, CALIFORNIA 

FRANCE PHILADELPHIA, PA. 

TURKEY LOS ANGELES, CALIFORNIA 

CHINA DETROIT, MICHIGAN 

TU RKEY LOS ANGELES, CALIFORN IA 

CHINA LOS ANGE LES, CALIFORNIA 

CHINA DETROIT, MICHIGAN 

CHINA CHARLESTON, S. CAROLINA 

IRELAND CHARLESTON, S. CAROLINA 

TURKEY LOS ANGELES, CALIFORNIA 

ITALY NORFOLK, VIRG INIA 

FRANCE PHILADELPHIA, PA. 

CHINA LOS ANGELES, CALIFORN IA 

IN DIA NEW YORK CITY, NEW YORK 

CHINA LOS ANGELES, CALIFORNIA 

CHINA DETROIT, MICHIGAN 

Client: 

Rochem International, Inc. 

07/12/2010 - 17:37 

District of Unlading 

NEW YORK CITY, NEW YORK 

NEW YORK CITY, NEW YORK 

LOS ANGELES, CALIFORNIA 

CHARLESTON, S. CAROLINA 

LOS ANGELES, CALIFORNIA 

LOS ANGELES, CALIFORNIA 

MOBILE, ALABAMA 

LOS ANGELES, CALIFORNIA 

CHICAGO, ILLINOIS 

NEW YORK CITY, NEW YORK 

PHILADELPHIA, PA. 

NEW YORK CITY, NEW YORK 

CHARLESTON, S. CAROLINA 

CHICAGO, ILLINOIS 

NEW YORK CITY, NEW YORK 

DETROIT, MICHIGAN 

CHARLESTON, S. CAROLINA 

SAN FRANCISCO, CALIF. 

CHARLESTON, S. CAROLINA 

NEW YORK CITY, NEW YORK 

LOS ANGELES, CALIFORNIA 

NEW YORK CITY, NEW YORK 

CLEVELAND, OHIO 

LOS ANGELES, CALIFORNIA 

LOS ANGELES, CALIFORNIA 

LOS ANGELES, CALIFORNIA 

LOS ANGELES, CALIFORNfA 

CHARLESTON, S. CAROLINA 

CHARLESTON, S. CAROLINA 

LOS ANGELES, CALIFORNIA 

NORFOLK, VIRGINIA 

NEW YORK CITY, NEW YORK 

LOS ANGELES, CALIFORNIA 

NEW YORK CITY, NEW YORK 

LOS ANGELES, CALIFORNIA 

LOS ANGELES, CALIFORNIA 

General Total 

Value CIF US$ 

337,718.00 

824,396.00 

116,408.00 

46,250.00 

145,872.00 

94,460.00 

29,920.00 

74,250.00 

61,341.00 

82,940.00 

104,648.00 

142,560.00 

66,928.00 

23,042.00 

232,816.00 

90,207.00 

195,600.00 

115,153.00 

46,250.00 

4,450.00 

116,408.00 

369,810.00 

116,408.00 

375,325 .00 

116,408.00 

54,320.00 

409,882.00 

260,800.00 

103,658.00 

453,047.00 

80,222.00 

738,761.00 

58,630.00 

40,503.00 

65,120.00 

662,119.00 

General General Consumption Consumpt ion 

General Total Quantity Unit Value Tot al Value CIF Total Value FOB 

Value FOB US$ (Kilograms) CIF US$ US$ US$ 

337,718.00 45,200.00 7.47 0 0 

792,049 .00 136,000.00 6.06 824,396.00 792,049.00 

86,160.00 12,000.00 9.7 116,408.00 86,160.00 

45,000.00 7,500.00 6.17 46,250.00 45,000.00 

144,000.00 32,000.00 4.56 0 0 

86,160.00 12,000.00 7.87 94,460.00 86,160.00 

24,920.00 3,000.00 9.97 29,920.00 24,920.00 

72,214.00 15,000.00 4.95 74,250.00 72,214.00 

52,499.00 2,019.00 30.38 61,341.00 52,499.00 

79,940.00 18,000.00 4.61 82,940.00 79,940.00 

74,400.00 12,000.00 8.72 104,648.00 74,400.00 

135,004.00 24,000.00 5.94 142,560.00 135,004.00 

64,723.00 12,600.00 5.31 66,928.00 64,723.00 

23,040.00 2,400.00 9.6 23,042.00 23,040.00 

172,320.00 24,000.00 9.7 232,816.00 172,320.00 

50,670.00 9,000.00 10.02 90,207.00 50,670.00 

184,476.00 30,000.00 6.52 195,600.00 184,476.00 

86,160.00 12,000.00 9.6 115,153.00 86,160.00 

45,000.00 7,500.00 6.17 46,250.00 45,000.00 

4,000.00 1 4,450.00 4,450.00 4,000.00 

86, 160.00 12,000.00 9.7 116,408.00 86, 160.00 

357,565.00 63,000.00 5.87 369,810.00 357,565.00 

86,160.00 14,160.00 8.22 116,408.00 86,160.00 

361,280.00 67,200.00 5.59 0 0 

86,160.00 12,000.00 9.7 116,408.00 86,160.00 

50,820.00 11,000.00 4.94 54,320.00 50,820.00 

386,680.00 66,400.00 6. 17 0 0 

245,168.00 40,000.00 6.52 260,800.00 245,168.00 

103,593.00 6,328.00 16.38 103,658.00 103,593 .00 

344,640.00 48,000.00 9.44 453,047.00 344,640.00 

77,722.00 11,047.00 7.26 80,222.00 77,722.00 

708,976.00 134,400.00 5.5 738,761.00 708,976.00 

56,680.00 11,000.00 5.33 58,630.00 56,680.00 

39,803.00 6,000.00 6.75 40,503.00 39,803.00 

63,170.00 11,000.00 5.92 65,120.00 63, 170.00 

624,640.00 102,400.00 6.47 0 0 
General General Consumpt ion Consumption 

Country of General Tot al General Total Quantity Unit Value Total Value CIF Total Value FOB 

Dat e Harmonized Code Purchase District of Entry District of Unlading Value CI F US$ Value FOB US$ (Kilograms) CIF US$ US$ US$ 

Sep-08 2924296210 CHINA PHILADELPHIA, PA. NEW YOR K CITY, NEW YORK 109,680.00 102,154.00 24,000.00 4.57 109,680.00 102,154.00 

Sep-08 2924296210 FRAN CE PHILADELPHIA, PA. NEW YORK CITY, NEW YORK 39,882.00 37,585.00 10,200.00 3.91 39,882.00 37,585.00 

Sep-08 2924296210 CH INA CHARLESTON, S. CAROLINA CHARLESTON, S. CAROLINA 130,400.00 122,584.00 20,000.00 6.52 130,400.00 122,584.00 

Sep-08 2924296210 TURKEY LOS ANGELES, CALIFORNIA LOS ANGELES, CALIFORNIA 117,173.00 86,160.00 12,000.00 9.76 117,173.00 86,160.00 

Aug-08 2924296210 CHINA LOS ANGELES, CALIFORNIA LOS ANGELES, CALI FORNIA 65,120.00 63,270.00 11,000.00 5.92 65,120.00 63,270.00 

Aug-08 2924296210 CHINA DETROIT, MICHIGAN LOS ANGELES, CALIFORNIA 456,734.00 430,880.00 92,800.00 4.92 0 0 

Aug-08 2924296210 IRELAND BALTIMORE, MARYLAND BALTIMORE, MARYLAND 14,844.00 6,886.00 1,617.00 9. 18 14,844.00 6,886.00 

Aug-08 2924296210 FRANCE PHILADELPHIA, PA. NEW YORK CITY, NEW YORK 150,117.00 144,325.00 24,600.00 6.1 150,117.00 144,325.00 

Aug-08 2924296210 TURKEY SAVANNAH, GEORGIA SAVANNAH, GEORGIA 226,764.00 217,764.00 41,400.00 5.48 226,764.00 217,764.00 

Aug-08 2924296210 CHINA PHILADELPHIA, PA. NEW YORK CITY, NEW YORK 25,800.00 24,800.00 4,000.00 6.45 25,800.00 24,800.00 

Aug-08 2924296210 CHINA DETROIT, M ICHIGAN CHICAGO, ILLINOIS 34,980.00 33,000.00 6,000.00 5.83 0 0 

Jul-08 2924296210 CHINA DETROIT, MICHIGAN LOS ANGELES, CALIFORNIA 71,232.00 67,200.00 19,200.00 3.71 0 0 

Jul-08 2924296210 CHINA DETROIT, MICHIGAN CHICAGO, ILLINOIS 198,432.00 187,200.00 32,000.00 6.2 0 0 

Jul-08 2924296210 FRAN CE PHI LADELPHIA, PA. NEW YORK CITY, NEW YORK 50,600.00 48,228.00 8,400.00 6.02 50,600.00 48,228.00 

Jul-08 2924296210 FRANCE CHARLESTON, S. CAROLINA CHARLESTON, S. CAROLINA 73,792.00 71,587.00 12,600.00 5.86 73,792.00 71,587.00 

Jul-08 2924296210 IRELAN D BALTIMORE, MARYLAND BALTIMORE, MARYLAND 4,780.00 2,944.00 600 7.97 4,780.00 2,944.00 

Jul-08 2924296210 CHINA LOS ANGELES, CALIFORNIA LOS ANGELES, CALIFORNIA 60,720.00 58,770.00 11,000.00 5.52 60,720.00 58,770.00 

Jul-08 2924296210 IRELAND CHARLESTON, S. CAROLI NA CHARLESTON, S. CAROLINA 287,729.00 287,329.00 13,579.00 21.19 287,729 .00 287,329.00 

Jul-08 2924296210 CHINA NEW YORK CITY, NEW YORK NEW YORK CITY, NEW YORK 72,180.00 69,180.00 18,000.00 4.01 72,180.00 69,180.00 

Jul-08 2924296210 TURKEY LOS ANGELES, CALIFORNIA LOS ANGELES, CALIFORNIA 152,981.00 148,800.00 24,000.00 6.37 152,981.00 148,800.00 

Jun-08 2924296210 CHI NA DETROIT, MICHIGAN CHICAGO, ILLINOIS 178,080.00 168,000.00 48,000.00 3.71 0 0 

Jun-08 2924296210 TURKEY NEW YORK CITY, NEW YORK NEW YORK CITY, NEW YORK 229,683.00 208,320.00 33,600.00 6.84 229,683 .00 208,320.00 

Jun-08 2924296210 TURKEY LOS ANGELES, CALIFORNIA LOS ANGELES, CALIFORNIA 102,304.00 89,280.00 14,400.00 7.1 102,304.00 89,280.00 

Jun-08 2924296210 CHINA NEW YORK CITY, NEW YORK NEW YORK CITY, NEW YORK 69,705.00 65,705.00 18,000.00 3.87 69,705.00 65,705.00 

Jun-08 2924296210 CHINA PHI LADELPHIA, PA. NEW YORK CITY, NEW YORK 87,990.00 80,483.00 21,000.00 4.19 87,990.00 80,483.00 

Jun-08 2924296210 CHI NA CHARLESTON, S. CAROLINA CHARLESTON, S. CAROLI NA 259,200.00 236,271.00 60,000.00 4.32 259,200.00 236,271.00 

Jun-08 2924296210 FRANCE CHARLESTON, S. CAROLINA CHARLESTON, S. CAROLINA 147,584.00 143,174 .00 25,200.00 5.86 147,584.00 143,174.00 

Jun-08 2924296210 CHINA LOS ANGELES, CALIFORNIA LOS ANGELES, CALIFORNIA 44,000.00 42,150.00 11,000.00 4 44,000.00 42,150.00 

M ay-08 2924296210 TURKEY CHICAGO, ILLINOIS CHICAGO, ILLINOIS 7,367.00 6,200.00 1,000.00 7.37 7,367.00 6,200.00 

May-08 2924296210 TURKEY LOS ANGELES, CALIFORN IA LOS ANGELES, CALIFORNIA 231,500.00 223,200.00 36,000.00 6.43 231,500.00 223,200.00 

May-08 2924296210 TURKEY M OBILE, ALABAMA SAVAN NAH, GEORGIA 529,116.00 508,116.00 96,600.00 5.48 529,116.00 508,116.00 

M ay-08 2924296210 FRANCE CHARLESTON, S. CAROLINA CHARLESTON, S. CAROLINA 144,081.00 139,671.00 25,200.00 5.72 144,081.00 139,671.00 

M ay-08 2924296210 TU RKEY PHILADELPHIA, PA. NEW YORK CITY, NEW YORK 236,700.00 223,200.00 36,000.00 6.58 236,700.00 223,200.00 

M ay-08 2924296210 CHINA DETROIT, MICHIGAN LOS ANGELES, CALIFORNIA 59,360.00 56,000.00 16,000.00 3.71 0 0 

M ay-08 2924296210 TU RKEY SAVANNAH, GEORGIA SAVANNAH, GEORGIA 88,570.00 88,320.00 13,800.00 6.42 88,570.00 88,320.00 

May-08 2924296210 FRANCE PHILADELPHIA, PA. NEW YORK CITY, NEW YOR K 73,962.00 71,587.00 12,600.00 5.87 73,962.00 71,587.00 

May-08 2924296210 CHINA PHILADELPHIA, PA. NEW YORK CITY, NEW YORK 87,980.00 80,473.00 22,000.00 4 87,980.00 80,473.00 

Apr-08 2924296210 FRANCE CHARLESTON, S. CAROLINA CHARLESTON, S. CAROLINA 67,004.00 64,799.00 12,600.00 5.32 67,004.00 64,799.00 

Apr-08 2924296210 CHINA CHARLESTON, S. CAROLINA CHARLESTON, S. CAROLINA 259,200.00 238,491.00 60,000.00 4.32 259,200.00 238,491.00 

Apr-08 2924296210 TURKEY MOBILE, ALABAMA SAVANNAH, GEORGIA 302,352.00 290,352 .00 55,200.00 5.48 302,352 .00 290,352.00 

Apr-08 2924296210 CHINA DETROIT, MICHIGAN CHICAGO, ILLINOIS 111,300.00 105,000.00 30,000.00 3.71 0 0 

Apr-08 2924296210 CHINA PH ILADELPHIA, PA. NEW YOR K CITY, NEW YOR K 175,538.00 168,108.00 31,600.00 5.56 175,538.00 168,108.00 

Apr-08 2924296210 FRAN CE PHILADELPHIA, PA. NEW YORK CITY, NEW YORK 236,334.00 226,432 .00 47,000.00 5.03 236,334 .00 226,432.00 

Apr-08 2924296210 CHINA CHICAGO, ILLINOIS CHICAGO, ILLINOIS 71,232.00 67,200.00 19,200.00 3.71 0 0 

Apr-08 2924296210 CHINA NEW YORK CITY, NEW YORK NEW YOR K CITY, NEW YORK 36,720.00 36,000.00 3,564.00 10.3 36,720.00 36,000.00 

Apr-08 2924296210 TURKEY LOS ANGELES, CALIFORNIA LOS ANGELES, CALIFORNIA 676,770.00 669,600.00 108,000.00 6.27 676,770.00 669,600.00 
Country of 

Date Harmonized Code Purchase District of Entry 

Apr-OB 2924296210 CHINA LOS ANGELES, CALIFORNIA 

Apr-OB 2924296210 INDIA NEW YORK CITY, NEW YORK 

Apr-OB 2924296210 TURKEY CHICAGO, ILLINOIS 

Mar-OB 2924296210 IRELAND CHARLESTON, S. CAROLINA 

M ar-OB 2924296210 FRANCE PHILADELPHIA, PA. 

M ar-OB 2924296210 INDIA BALTIMORE, MARYLAND 

Mar-OB 2924296210 CHINA PHILADELPHIA, PA. 

Mar-OB 2924296210 TURKEY CHICAGO, ILLINOIS 

Mar-OB 2924296210 CHINA CHARLESTON, S. CAROLINA 

M ar-OB 2924296210 TURKEY M OBILE, ALABAMA 

Mar-OB 2924296210 TURKEY PHILADELPHIA, PA. 

Feb-OB 2924296210 CHINA NEW YORK CITY, NEW YORK 

Feb-OB 2924296210 CHINA NEW YORK CITY, NEW YORK 

Feb-OB 2924296210 TURKEY LOS ANGELES, CALIFORNIA 

Feb-OB 2924296210 TURKEY MOBILE, ALABAMA 

Feb-OB 2924296210 FRANCE PHI LADELPHIA, PA. 

Feb-OB 2924296210 FRANCE CHARLESTON, S. CAROLINA 

Jan-OB 2924296210 TURKEY SAVAN NAH, GEORGIA 

Jan-OB 2924296210 TURKEY MOBILE, ALABAMA 

Jan-OB 2924296210 IN DIA BALTIMORE, MARYLAND 

Jan-OB 2924296210 CHINA LOS ANGELES, CALIFORNIA 

Jan-OB 2924296210 FRANCE PHILADELPHIA, PA. 

Jan-OB 2924296210 CHINA MIAMI, FLORDIA 

Jan-OB 2924296210 FRANCE CHARLESTON, S. CAROLINA 

Jan-OB 2924296210 CHINA NEW YORK CITY, NEW YORK 

Jan-OB 2924296210 CHINA DETROIT, M ICHIGAN 

TOTAL 

General Total 

District of Unlading Value CIF US$ 

LOS ANGELES, CALI FORN IA 47,000.00 

NEW YORK CITY, NEW YORK 11,96B.00 

LOS ANGELES, CALIFORNIA 375,560.00 

CHARLESTON, S. CAROLINA 219,565.00 

NEW YORK CITY, NEW YORK 127,95B.00 

NEW YORK CITY, NEW YORK 4,275.00 

NEW YORK CITY, NEW YORK 16,000.00 

LOS ANGELES, CALI FORNIA 76,3BO.00 

CHARLESTON, S. CAROLINA B6, 257.00 

SAVANNAH, GEORGIA 271,440.00 

NEW YORK CITY, NEW YORK 197,272.00 

NEW YORK CITY, NEW YORK 211,192.00 

NEW YORK CITY, NEW YORK 55,B26.00 

LOS ANGELES, CALIFORNIA 29B,340.00 

SAVANNAH, GEORGIA 269,440.00 

NEW YORK CITY, NEW YORK 303,492.00 

CHARLESTON, S. CAROLINA 162,633.00 

SAVANNAH, GEORGIA BB,720.00 

SAVANNAH, GEORGIA 279,440.00 

NEW YORK CITY, NEW YORK 4,271.00 

LOS ANGELES, CALIFORN IA 82,500.00 

NEW YORK CITY, NEW YORK 162,6BO.00 

M IAM I, FLORDIA 41,500.00 

CHARLESTON, S. CAROLI NA 67,004.00 

NEW YORK CITY, NEW YOR K 16B,112.00 

LOS ANGELES, CALIFORNIA 187,626.00 

17,530,653.00 

Figures hold to seasonal adjustments and rounding 

Source: U.S. Census Bureau. 

www.datamyne.com 

Email: info@datamyne.com 

© 2005-2010 The Datamyne - Terms of Use 

Privacy Policy 

General General Consumption Consumption 

General Total Quantity Unit Value Total Value CIF Total Value FOB 

Value FOB US$ (Kilograms) CIF US$ US$ US$ 

45,150.00 10,009.00 4.7 47,000.00 45,150.00 

11,7B3.00 3,000.00 3.99 11,96B.00 11,7B3.00 

372,000.00 60,000.00 6.26 375,560.00 372,000.00 

219,495.00 11,941.00 lB.39 219,565.00 219,495.00 

123,254.00 2B,600.00 4.47 127,95B.00 123,254.00 

4,250.00 500 B.55 4,275 .00 4,250.00 

15,500.00 4,000.00 4 16,000.00 15,500.00 

74,400.00 12,000.00 6.37 76,3BO.00 74,400.00 

79,497.00 20,000.00 4.31 B6,257.00 79,497.00 

259,440.00 55,200.00 4.92 271,440.00 259,440.00 

192,372.00 27,600.00 7.15 197,272.00 192,372.00 

203,575.00 5B,000.00 3.64 211,192.00 203,575.00 

52,500.00 15,000.00 3.72 55,B26.00 52,500.00 

297,600.00 4B,000.00 6.22 29B,340.00 297,600.00 

259,440.00 55,200.00 4.BB 269,440.00 259,440.00 

290,147.00 59,600.00 5.09 303,492.00 290,147.00 

15B,223.00 28,BOO.00 5.65 162,633.00 158,223.00 

BB,320.00 13,BOO.OO 6.43 BB,720.00 BB,320.00 

259,440.00 55,200.00 5.06 279,440.00 259,440.00 

4,250.00 500 B. 54 4,271.00 4,250.00 

78,700.00 22,000.00 3.75 82,500.00 7B,700.00 

157,B96 .00 34,000.00 4.7B 162,6BO.00 157,B96.00 

39,000.00 10,000.00 4.15 41,500.00 39,000.00 

64,799.00 12,600.00 5.32 67,004.00 64,799.00 

15B,350.00 63,000.00 2.67 16B,112.00 15B,350.00 

177,004.00 54,BOO.00 3.42 0 0 

16,432,833.00 3,040,065.00 14230761 132B7031 
C-75
· UNITED STATES - IMPORT 

Period 

Harmonized Code 

Date Harmonized Code 

Dec-09 2924296210 

Dec-09 2924296210 

Dec-09 2924296210 

Dec-09 2924296210 

Dec-09 2924296210 

Dec-09 2924296210 

Dec-09 2924296210 

Dec-09 2924296210 

Nov-09 2924296210 

Nov-09 2924296210 

Nov-09 2924296210 

Nov-09 2924296210 

Nov-09 2924296210 

Nov-09 2924296210 

Nov-09 2924296210 

Nov-09 2924296210 

Nov-09 2924296210 

Oct-09 2924296210 

Oct-09 2924296210 

Oct-09 2924296210 

Oct-09 2924296210 

Oct-09 2924296210 

Oct-09 2924296210 

Oct-09 2924296210 

Oct-09 2924296210 

01/2009 to 12/2009 

2924296210 - ACETAMINOPHEN 

Country of 

Purchase District of Entry 

CHI NA DETROIT, MICHIGAN 

TU RKEY LOS ANGELES, CALIFORNIA 

CHINA LOS ANGELES, CALIFORNIA 

INDIA NEW ORLEANS, LOUISIANA 

CHINA NEW YORK CITY, NEW YORK 

CHINA PHILADELPHIA, PA. 

TURKEY SAVANNAH, GEORGIA 

CHINA CHARLESTON, S. CAROLINA 

CHINA LOS ANGELES, CALIFORNIA 

CHINA PHILADELPHIA, PA. 

CHINA DETROIT, MICHIGAN 

CHINA CHICAGO, ILLINOIS 

IRELAND CHARLESTON, S. CAROLINA 

CH INA NEW YORK CITY, NEW YORK 

TURKEY SAVANNAH, GEORGIA 

CHINA DETROIT, MICHIGAN 

TU RKEY LOS ANGELES, CALI FORNIA 

CHINA PHILADELPHIA, PA. 

CHINA PHILADELPHIA, PA. 

TURKEY PHILADELPHIA, PA. 

CHINA DETROIT, MICHIGAN 

TU RKEY LOS ANGELES, CALIFORNIA 

IRELAND CHARLESTON, S. CAROLINA 

CH INA LOS ANGELES, CALIFORNIA 

FRANCE CHICAGO, ILLINOIS 

Client: 

Rochem International, Inc. 

07/06/2010 - 16:43 

District of Unlading 

SEATILE, WASHINGTON 

LOS ANGELES, CALIFORNIA 

LOS ANGELES, CALIFORN IA 

CHARLESTON, S. CAROLINA 

NEW YORK CITY, NEW YORK 

NEW YORK CITY, NEW YORK 

SAVANNAH, GEORGIA 

CHARLESTON, S. CAROLINA 

LOS ANGELES, CALIFORNIA 

NEW YORK CITY, NEW YORK 

CHICAGO, ILLINOIS 

LOS ANGELES, CALIFORNIA 

CHARLESTON, S. CAROLINA 

NEW YORK CITY, NEW YORK 

SAVANNAH, GEORGIA 

SEATILE, WASHINGTON 

LOS ANGELES, CALIFORNIA 

NEW YORK CITY, NEW YORK 

SEATILE, WASHI NGTON 

NEW YORK CITY, NEW YORK 

SEATILE, WASHINGTON 

LOS ANGELES, CALIFORNIA 

CHARLESTON, S. CAROLINA 

LOS ANGELES, CALIFORNIA 

CHICAGO, ILLINOIS 

General Total 

Value CIF US$ 

130,960.00 

1,010,180.00 

411,450.00 

36, 275.00 

131,700.00 

99,600.00 

104,414.00 

275,690.00 

199,273.00 

49,800.00 

65,480.00 

6,391.00 

77,997.00 

73,540.00 

91,320.00 

65,480.00 

797,790.00 

97,440.00 

48,720.00 

207,740.00 

196,440.00 

730,580.00 

99,757.00 

443,676.00 

0 

General Consumption Consumption 

General Total General Quantity Unit Value Total Value CIF Total Value FOB 

Value FOB US$ (Kilograms) CIF US$ US$ US$ 

129,280.00 32,000.00 4.09 0 0 

947,760.00 132,000.00 7.65 1,010,180.00 947,760.00 

406,993.00 96,000.00 4.29 411,450.00 406,993.00 

35,025.00 7,500.00 4.84 36,275.00 35,025.00 

124,700.00 30,000.00 4.39 131,700.00 124,700.00 

92,604.00 24,000.00 4.15 99,600.00 92,604.00 

103,914.00 13,800.00 7.57 104,414.00 103,914.00 

269,190.00 60,000.00 4.59 275,690.00 269,190.00 

196,320.00 43,823.00 4.55 199,273.00 196,320.00 

46,457.00 12,000.00 4.15 49,800.00 46,457.00 

64,640.00 16,000.00 4.09 0 0 

4,848.00 1,200.00 5.33 6,391.00 4,848.00 

77,697.00 2,226.00 35.04 77,997.00 77,697.00 

71,540.00 18,000.00 4.09 73,540.00 71,540.00 

88,320.00 13,800.00 6.62 91,320.00 88,320.00 

64,640.00 16,000.00 4.09 0 0 

775,440.00 108,000.00 7.39 797,790.00 775,440.00 

90,684.00 24,000.00 4.06 97,440.00 90,684.00 

44,137.00 12,000.00 4.06 48,720.00 44,137.00 

204,240.00 27,600.00 7.53 207,740.00 204,240.00 

193,920.00 48,000.00 4.09 0 0 

689,280.00 96,000.00 7.61 730,580.00 689,280.00 

99,682.00 2,856.00 34.93 99,757.00 99,682.00 

439,670.00 109,000.00 4.07 443,676.00 439,670.00 

0 0 0 324,899.00 323,899.00 
General Consumption Consumption 

Country of General Total General Total General Quantity Unit Value Tota l Value CIF Total Value FOB 

Date Harmonized Code Purchase District of Entry District of Unlading Value CIF US$ Value FOB US$ (Kilograms) CIF US$ US$ US$ 

Oct-09 2924296210 CHINA CHARLESTON, S. CAROLINA CHARLESTON, S. CAROLINA 47,415.00 44,915.00 10,000.00 4.74 47,415 .00 44,915.00 

Oct-09 2924296210 CHINA NEW YORK CITY, NEW YORK NEW YORK CITY, NEW YORK 89,200.00 86,000.00 20,000.00 4.46 89,200.00 86,000.00 

Oct-09 2924296210 INDIA NEW ORLEANS, LOUISIANA CHARLESTON, S. CAROLINA 37,550.00 36,300.00 7,500.00 5.01 37,550.00 36,300.00 

Sep-09 2924296210 INDIA NEW ORLEANS, LOUISIANA CHARLESTON, S. CAROLINA 75, 100.00 72,600.00 15,000.00 5.01 75,100.00 72,600.00 

Sep-09 2924296210 CHINA LOS ANGELES, CALIFORNIA LOS ANGELES, CALIFORNIA 359,825.00 356,670.00 85,000.00 4.23 359,825.00 356,670.00 

Sep-09 2924296210 CHINA MIAMI, FLORDIA M IAMI, FLORDIA 3,086.00 2,935.00 500 6.17 0 0 

Sep-09 2924296210 CH INA DETROIT, MICHIGAN SEATILE, WASHINGTON 130,960.00 129,280.00 32,000.00 4.09 0 0 

Sep-09 2924296210 TURKEY LOS ANGELES, CALIFORNIA LOS ANGELES, CALIFORN IA 448,500.00 430,800.00 60,000.00 7.48 448,500.00 430,800.00 

Sep-09 2924296210 CH INA NEW YORK CITY, NEW YORK NEW YORK CITY, NEW YORK 87,200.00 84,000.00 20,000.00 4.36 87,200.00 84,000.00 

Sep-09 2924296210 CHINA PHILADELPH IA, PA. NEW YORK CITY, NEW YORK 121,191.00 114,377.00 29,850.00 4.06 121,191.00 114,377.00 

Sep-09 2924296210 CHINA CHARLESTON, S. CAROLINA CHARLESTON, S. CAROLINA 98,400.00 96,400.00 20,000.00 4.92 98,400.00 96,400.00 

Aug-09 2924296210 INDIA NEW ORLEANS, LOUISIANA SAVAN NAH, GEORGIA 35,450.00 34,200.00 7,500.00 4.73 35,450.00 34,200.00 

Aug-09 2924296210 CH INA LOS ANGELES, CALIFORNIA LOS ANGELES, CALIFORNIA 324,008.00 324,000.00 80,000.00 4.05 324,008.00 324,000.00 

Aug-09 2924296210 CHINA SAVANNAH, GEORGIA NEW YORK CITY, NEW YORK 7,800.00 7,734.00 1,500.00 5.2 7,800.00 7,734.00 

Aug-09 2924296210 TURKEY SAVANNAH, GEORGIA SAVANNAH, GEORGIA 547,920.00 529,920.00 82,800.00 6.62 547,920.00 529,920.00 

Aug-09 2924296210 TURKEY LOS ANGELES, CALIFORNIA LOS ANGELES, CALIFORNIA 463,334.00 406,336.00 55,200.00 8.39 463,334.00 406,336.00 

Aug-09 2924296210 CHINA DETROIT, MICHIGAN SEATILE, WASH INGTON 211,805.00 209,088.00 51,200.00 4.14 0 0 

Aug-09 2924296210 CHINA PHI LADELPHIA, PA. PHI LADELPHIA, PA. 146,160.00 137,181.00 36,000.00 4.06 146,160.00 137,181.00 

Aug-09 2924296210 IRELAND CHARLESTON, S. CAROLINA CHARLESTON, S. CAROLINA 181,586.00 179,086.00 5,527.00 32.85 181,586.00 179,086.00 

Aug-09 2924296210 ITALY NORFOLK, VIRGINIA NORFOLK, VIRGINIA 90,256.00 89,756.00 3,387.00 26.65 90,256.00 89,756.00 

Jul-09 2924296210 IRELAND CHARLESTON, S. CAROLINA CHARLESTON, S. CAROLINA 95,664.00 92,164.00 2,863 .00 33.41 95,664.00 92,164.00 

Jul-09 2924296210 CHINA DETROIT, MICHIGAN LOS ANGELES, CALIFORNIA 133,229.00 131,520.00 32,000.00 4. 16 0 0 

Jul-09 2924296210 TURKEY SAVANNAH, GEORGIA SAVANNAH, GEORGIA 592,160.00 572,160.00 89,400.00 6.62 592, 160.00 572,160.00 

Ju l-09 2924296210 CHINA LOS ANGELES, CALIFORNIA LOS ANGELES, CALI FORNIA 198,290.00 194,670.00 45,000.00 4.41 198,290.00 194,670.00 

Jul-09 2924296210 TURKEY LOS ANGELES, CALIFORNIA LOS ANGELES, CALIFORNIA 658,390.00 551,424.00 76,800.00 8.57 658,390.00 551,424.00 

Jul-09 2924296210 TURKEY LOS ANGELES, CALIFORNIA NEW YORK CITY, NEW YORK 102,856.00 86, 160.00 12,000.00 8.57 102,856.00 86,160.00 

Jul-09 29242962 10 CHINA NEW YORK CITY, NEW YORK NEW YORK CITY, NEW YORK 73,110.00 71,110.00 18,000.00 4.06 73,110.00 71,110.00 

Jun-09 2924296210 CANADA NEW ORLEANS, LOUISIANA NEW ORLEANS, LOUISIANA 8,625.00 8,175.00 1 8,625.00 8,625.00 8,175.00 

Jun-09 2924296210 CHINA LOS ANGELES, CALIFORNIA LOS ANGELES, CALIFORN IA 151,353.00 147,360.00 33,000.00 4.59 151,353.00 147,360.00 

Jun-09 2924296210 INDIA NEW YORK CITY, NEW YORK NEW YORK CITY, NEW YORK 3,192.00 3,000.00 3,000.00 1.06 3,192.00 3,000.00 

Jun-09 2924296210 INDIA DETROIT, MICHIGAN DETROIT, MICHIGAN 5,755.00 4,200.00 400 14.39 5,755.00 4,200.00 

Jun-09 2924296210 TURKEY LOS ANG ELES, CALIFORNIA LOS ANGELES, CALIFORNIA 784,997.00 654,816.00 91,200.00 8.61 784,997.00 654,816.00 
o 

.!..J 

OJ 

Date 

Jun-09 

Jun-09 

Jun-09 

Jun-09 

Jun-09 

Jun-09 

May-09 

May-09 

May-09 

May-09 

M ay-09 

M ay-09 

May-09 

Apr-09 

Apr-09 

Apr-09 

Apr-09 

Apr-09 

Apr-09 

Apr-09 

Apr-09 

Mar-09 

Mar-09 

Mar-09 

Mar-09 

Mar-09 

Mar-09 

Mar-09 

Mar-09 

Mar-09 

Ma r-09 

Mar-09 

Harmonized Code 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

29242962 10 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

29242962 10 

2924296210 

2924296210 

2924296210 

2924296210 

29242962 10 

29242962 10 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

Country of 

Purchase 

INDIA 

TURKEY 

CHINA 

CHINA 

CHINA 

TURKEY 

CHINA 

CHINA 

IRELAND 

TURKEY 

TURKEY 

TURKEY 

CHINA 

CHINA 

IN DIA 

TURKEY 

CHINA 

TURKEY 

TURKEY 

CHINA 

CHINA 

TURKEY 

INDIA 

TURKEY 

CHINA 

TURKEY 

CHINA 

TURKEY 

TURKEY 

CHINA 

IRELAND 

FRANCE 

General Total 

District of Entry District of Unlading Value CIF US$ 

NEW ORLEANS, LOUISIANA CHARLESTON, S. CAROLINA 72, 150.00 

LOS ANGELES, CALIFORNIA NEW YORK CITY, NEW YORK 42,104.00 

NEW YORK CITY, NEW YORK NEW YORK CITY, NEW YORK 164,480.00 

DETROIT, MICHIGAN SEATILE, WASHINGTON 67,749.00 

DETROIT, MICHIGAN LOS ANGELES, CALIFORNIA 81,299.00 

SAVANNAH, GEORGIA SAVAN NAH, GEORGIA 547,920.00 

DETROIT, MICHIGAN LOS ANGELES, CALIFORNIA 230,347.00 

CHARLESTON, S. CAROLINA CHARLESTON, S. CAROLINA 100,748.00 

CHARLESTON, S. CAROLINA CHARLESTON, S. CAROLI NA 157,503.00 

LOS ANGELES, CALIFORNIA LOS ANGELES, CALIFORNIA 592,258.00 

LOS ANGELES, CALIFORNIA NEW YORK CITY, NEW YORK 162,426.00 

SAVANNAH, GEORGIA SAVANNAH, GEORGIA 1,003,278.00 

PHILADELPHIA, PA. NEW YORK CITY, NEW YORK 71,280.00 

CHARLESTON, S. CAROLINA CHARLESTON, S. CAROLI NA 161,882.00 

NEW ORLEANS, LOUISIANA CHARLESTON, S. CAROLI NA 46,250.00 

SAVANNAH, GEORGIA SAVAN NAH, GEORGIA 821,880.00 

NEW YORK CITY, NEW YORK NEW YORK CITY, NEW YORK 170,906.00 

LOS ANGELES, CALIFORNIA LOS ANGELES, CALIFORNIA 520,046.00 

LOS ANGELES, CALIFORNIA PH ILADELPHIA, PA. 173,854.00 

LOS ANGELES, CALIFORN IA LOS ANGELES, CALIFORNIA 47,170.00 

DETROIT, MICHIGAN LOS ANGELES, CALIFORNIA 67,749.00 

LOS AN GELES, CALIFORNIA CLEVELAND, OHIO 116,408.00 

NEW ORLEANS, LOUISIANA CHARLESTON, S. CAROLINA 92,500.00 

LOS ANGELES, CALIFORNIA LOS ANGELES, CALIFORNIA 582,040.00 

NEW YORK CITY, NEW YORK NEW YORK CITY, NEW YORK 69,050.00 

SAVANNAH, GEORGIA SAVANNAH, GEORGIA 544,920.00 

CLEVELAND, OHIO CHICAGO, ILLINOIS 4,090.00 

NEW YORK CITY, NEW YORK NEW YORK CITY, NEW YORK 112,491.00 

LOS ANGELES, CALIFORN IA PHILADELPHIA, PA. 116,408.00 

BUFFALO, NEW YORK BU FFALO, NEW YORK 25,402.00 

CHARLESTON, S. CAROLINA CHARLESTON, S. CAROLINA 152,073.00 

CHICAGO, ILLINOIS NEW YORK CITY, NEW YORK 486,456.00 

General Consumption Consumption 

General Total General Quantity Unit Value Total Value CIF Total Value FOB 

Value FOB US$ (Kilograms) CIF US$ US$ US$ 

68,400.00 15,000.00 4.81 72,150.00 68,400.00 

34,464.00 4,800.00 8.77 42,104.00 34,464.00 

158,067.00 32,000.00 5.14 164,480.00 158,067.00 

66,880.00 16,000.00 4.23 0 0 

80,256.00 19,200.00 4.23 0 0 

529,920.00 82,800.00 6.62 547,920.00 529,920.00 

227,392.00 54,400.00 4.23 0 0 

97,508.00 27,600.00 3.65 100,748.00 97,508.00 

156,003 .00 5,622.00 28.02 157,503.00 156,003.00 

473,880.00 66,000.00 8.97 592,258.00 473,880.00 

129,240.00 18,000.00 9.02 162,426.00 129,240.00 

970,278.00 40,020.00 25.07 1,003, 278.00 970,278.00 

67,502.00 12,000.00 5.94 71,280.00 67,502 .00 

155,982.00 27,600.00 5.87 161,882.00 155,982 .00 

45,000.00 7,500.00 6.17 46,250.00 45,000.00 

794,880.00 12,420.00 66.17 821,880.00 794,880.00 

165,809.00 39,600.00 4.32 170,906.00 165,809.00 

387,720.00 54,000.00 9.63 520,046.00 387,720.00 

129,240.00 18,000.00 9.66 173,854.00 129,240.00 

43,670.00 11,000.00 4.29 47,170.00 43,670.00 

66,880.00 16,000.00 4.23 0 0 

86,160.00 12,000.00 9.7 116,408.00 86,160.00 

90,000.00 15,000.00 6.17 92,500.00 90,000.00 

430,800.00 60,000.00 9.7 582,040.00 430,800.00 

67,050.00 18,000.00 3.84 69,050.00 67,050.00 

529,920.00 82,800.00 6.58 544,920.00 529,920.00 

3,840.00 300 13.63 4,090.00 3,840.00 

103,914.00 13,800.00 8.15 112,491.00 103,914.00 

86,160.00 12,000.00 9.7 116,408.00 86,160.00 

24,313.00 6,950.00 3.65 25,402.00 24,313.00 

150,573.00 5,711.00 26.63 152,073.00 150,573.00 

486,456.00 64,000.00 7.6 0 0 
o 

~ to 

Date 

Feb-09 

Feb-09 

Feb-09 

Feb-09 

Feb-09 

Feb-09 

Feb-09 

Feb-09 

Feb-09 

Feb-09 

Jan-09 

Jan-09 

Jan-09 

Jan-09 

Jan-09 

Jan-09 

Jan-09 

Jan-09 

Jan-09 

Jan-09 

TOTAL 

Harmonized Code 

2924296210 

29242962 10 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

2924296210 

Country of 

Purchase 

CHINA 

CHINA 

CHINA 

TURKEY 

CHINA 

FRANCE 

CH INA 

FRANCE 

TURKEY 

INDIA 

TU RKEY 

CHINA 

TURKEY 

CHINA 

FRANCE 

CHINA 

CHINA 

CHINA 

CHINA 

CHINA 

District of Entry 

MOBILE, ALABAMA 

NEW YORK CITY, NEW YORK 

MIAMI, FLORDIA 

SAVANNAH, GEORGIA 

DETROIT, MICHIGAN 

CHARLESTON, S. CAROLINA 

BUFFALO, NEW YORK 

CHICAGO, ILLINOIS 

LOS ANGELES, CALIFORNIA 

NEW ORLEANS, LOUISIANA 

SAVANNAH, GEORGIA 

NEW YORK CITY, NEW YORK 

LOS ANGELES, CALIFORNIA 

DETROIT, MICHIGAN 

CHICAGO, ILLINOIS 

NEW YORK CITY, NEW YORK 

CHICAGO, ILLINOIS 

LOS ANGELES, CALIFORNIA 

PHILADELPHIA, PA. 

CHARLESTON, S. CAROLINA 

General Total 

District of Unlading Value CIF US$ 

LOS ANGELES, CALIFORNIA 44,800.00 

NEW YORK CITY, NEW YORK 20,000.00 

M IAMI, FLORDIA 13,565.00 

SAVANNAH, GEORGIA 744,050.00 

LOS ANGELES, CALIFORNIA 171,934.00 

CH ARLESTON, S. CAROLINA 219,339.00 

BUFFALO, NEW YORK 25,200.00 

NEW YORK CITY, NEW YORK 555,579.00 

LOS ANGELES, CALIFORNIA 232,816.00 

CHARLESTON, S. CAROLINA 46,250.00 

SAVANNAH, GEORGIA 273,960.00 

NEW YORK CITY, NEW YORK 101,805.00 

LOS ANGELES, CALIFORNIA 232,816.00 

LOS ANGELES, CALIFORNIA 242,795.00 

NEW YORK CITY, NEW YORK 850,014.00 

NEW YORK CITY, NEW YORK 93,581.00 

SEATILE, WASH INGTON 24,295.00 

LOS ANGELES, CALIFORNIA 48,270.00 

NEW YORK CITY, NEW YORK 63,090.00 

CHARLESTON, S. CAROLINA 334,800.00 

23,710,136.00 

Figures hold to seasonal adjustments and rounding 

Source: U.S. Census Bureau. 

www.datamyne.com 

Email: info@datamyne.com 

© 2005-2010 The Datamyne - Terms of Use 

Privacy Policy 

General Consumption Consumption 

General Total General Quantity Unit Value Total Value CIF Total Value FOB 

Value FOB US$ (Kilograms) CIF US$ US$ US$ 

41,800.00 4,000.00 11.2 44,800.00 41,800.00 

19,250.00 5,000.00 4 20,000.00 19,250.00 

13,480.00 725 18.71 0 0 

721,050.00 110,400.00 6.74 744,050.00 721,050.00 

169,728.00 38,400.00 4.48 0 0 

212,724.00 37,800.00 5.8 219,339.00 212,724.00 

24,415.00 7,000.00 3.6 25,200.00 24,415.00 

555,579.00 72,000.00 7.72 0 0 

172,320.00 24,000.00 9.7 232,816.00 172,320.00 

45,000.00 7,500.00 6.17 46,250.00 45,000.00 

264,960.00 41,400.00 6.62 273,960.00 264,960.00 

97,610.00 22,000.00 4.63 101,805.00 97,610.00 

172,320.00 26,160.00 8.9 232,816.00 172,320.00 

239,680.00 54,400.00 4.46 0 0 

850,014.00 113,600.00 7.48 0 0 

90,000.00 20,000.00 4.68 93,581.00 90,000.00 

22,723.00 5,400.00 4.5 24,295.00 22,723.00 

44,770.00 11,000.00 4.39 48,270.00 44,770.00 

58,726.00 13,500.00 4.67 63,090.00 58,726.00 

314, 112.00 60,000.00 5.58 334,800.00 314,112.00 

22,187,736.00 3,516,841.00 9526.36 20330108 18829987 
C-80
C-81
<;"> 

(Xl 

N 

UNITED STATES - IMPORT 

Period 

Harmonized Code 

Harmonized 

Date Code 

Apr-l0 2924296210 

Apr-l0 2924296210 

Apr-l0 2924296210 

Apr-l 0 2924296210 

Apr-lO 2924296210 

Apr-l0 2924296210 

Mar-l0 2924296210 

M ar-l0 2924296210 

Mar-l0 2924296210 

Mar-l 0 2924296210 

Feb-l0 2924296210 

Feb-l0 2924296210 

Feb-l 0 2924296210 

Feb-l0 2924296210 

Feb-lO 2924296210 

01/2010 to 04/2010 

2924296210 - ACETAMINOPHEN 

Country of 

Purchase District of Entry 

CHINA LOS ANG ELES, CALIFORNIA 

CHINA NEW YORK CITY, NEW YORK 

INDIA NEW ORLEANS, LOUISIANA 

TURKEY LOS ANGELES, CALIFORNIA 

TURKEY SAVANNAH, GEORGIA 

CHINA CHARLESTON, S. CAROLI NA 

CHINA NEW YO RK CITY, NEW YORK 

CHI NA LOS ANGELES, CALIFORNIA 

TURKEY SAVANNAH, GEORGIA 

TURKEY LOS ANGELES, CALIFORNIA 

TURKEY SAVANNAH, GEORGIA 

TURKEY SAVANNAH, GEORGIA 

CHI NA LOS ANGELES, CALIFORNIA 

CHINA PHILADELPHIA, PA. 

CHINA NEW YORK CITY, NEW YORK 

Client: 

Rochem International, Inc. 

07/06/2010 - 16:44 

District of Unlading 

LOS ANGELES, CALIFORNIA 

NEW YOR K CITY, NEW YORK 

SAVANNAH, GEORGIA 

LOS ANGELES, CALIFORNIA 

SAVANNAH, GEORGIA 

CHARLESTON, S. CAROLINA 

NEW YORK CITY, NEW YORK 

LOS ANGELES, CALIFORNIA 

SAVANNAH, GEORGIA 

LOS ANGELES, CALIFORNIA 

SAVANNAH, GEORGIA 

NEW YO RK CITY, NEW YORK 

LOS ANGELES, CALIFORNIA 

NEW YORK CITY, NEW YORK 

NEW YORK CITY, NEW YORK 

General Total 

Value CIF US$ 

261,006.00 

87,950.00 

72,716.00 

189,390.00 

91,320.00 

186,373.00 

103,200.00 

431,657.00 

273,960.00 

663,410.00 

471,194.00 

106,950.00 

349,824.00 

49,800.00 

72,900.00 

General Consumption Consumption 

General Total Quantity General Unit Total Value CIF Total Value FOB 

Value FOB US$ (Kilograms) Value CIF US$ US$ US$ 

261,000.00 40,000.00 6.53 261,006.00 261,000.00 

87,000.00 20,000.00 4.4 87,950.00 87,000.00 

71,869.00 15,000.00 4.85 72,716.00 71,869.00 

172,320.00 24,000.00 7.89 189,390.00 172,320.00 

88,320.00 13,800.00 6.62 91,320.00 88,320.00 

182,518.00 40,000.00 4.66 186,373.00 182,518.00 

102,000.00 19,600.00 5. 27 103,200.00 102,000.00 

430,000.00 94,000.00 4.59 431,657.00 430,000.00 

264,960.00 41,400.00 6.62 273,960.00 264,960.00 

603,120.00 84,000.00 7.9 663,410.00 603,120.00 

457,194.00 69,000.00 6.83 471,194.00 457,194.00 

79,252.00 13,800.00 7.75 106,950.00 79,252.00 

345,620.00 81,000.00 4.32 349,824.00 345,620.00 

46,477.00 12,000.00 4.15 49,800.00 46,477.00 

71,900.00 18,000.00 4.05 72,900.00 71,900.00 
Harmonized Country of 

Date Code Purchase District of Entry 

Feb-10 2924296210 TU RKEY LOS ANGELES, CALI FORNIA 

Ja n-10 2924296210 CHINA LOS AN GELES, CALIFORNIA 

Ja n-10 2924296210 INDIA DETROIT, MICHIGAN 

Jan-10 2924296210 CHINA CHARLESTON, S. CAROLINA 

Jan-10 2924296210 INDIA NEW OR LEANS, LOUISIANA 

Jan-10 2924296210 TURKEY SAVANNAH, GEORGIA 

Jan-10 2924296210 CHINA DETROIT, MICHIGAN 

Jan-10 2924296210 CHINA PHI LADELPH IA, PA. 

Ja n-10 2924296210 TURKEY LOS ANGELES, CALIFORNIA 

TOTAL 

General Total General Total 

District of Unlading Value CIF US$ Value FOB LlS$ 

LOS ANGELES, CALIFORNIA 662,770.00 

LOS ANGELES, CALIFORNIA 264,724.00 

DETROIT, MICHIGAN 14,970.00 

CHARLESTON, S. CAROLINA 45,865.00 

SAVANNAH, GEORGIA 72,550.00 

SAVANNAH, GEORGIA 182,640.00 

LOS ANGELES, CALIFORNIA 65,480.00 

NEW YORK CITY, NEW YORK 49,800.00 

LOS ANGELES, CALIFORNIA 852,490.00 

5,622,939.00 

Figures hold to seasonal adjustments and rounding 

Source: U.S. Census Burea u. 

www.datamyne .com 

Email: info@datamyne.com 

© 2005-2010 The Datamyne - Terms of Use 

Privacy Policy 

603,120.00 

261,720.00 

11,160.00 

44,865.00 

70,050.00 

176,640.00 

64,640.00 

46,302.00 

775,440.00 

5,317,487.00 

General Consumption Consumption 

Quantity General Unit Total Value CIF Tota l Value FOB 

(Ki lograms) Value CIF US$ US$ US$ 

84,000.00 7.89 662,770.00 603,120.00 

62,000.00 4.27 264,724.00 261,720.00 

1,200.00 12.48 14,970.00 11,160.00 

10,000.00 4.59 45,865.00 44,865.00 

15,000.00 4.84 72,550.00 70,050.00 

27,600.00 6.62 182,640.00 176,640.00 

16,000.00 4.09 0 0 

12,000.00 4.15 49,800.00 46,302.00 

108,000.00 7.89 852,490.00 775,440.00 

921,400.00 5,557,459.00 5,252,847.00 
C-84
C-85
C-86
C-87
C-88